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ABSTRACT

Molly M. Leeper
Trends in Toxin Profiles of Human Shiga Toxin-Producing Escherchia coli (STEC)
O157 Strains, United States, 1996-2008
(Under the direction of Dr. Karen Gieseker, faculty member)

Shiga toxin-producing E. coli (STEC) cause diarrhea, hemorrhagic colitis, and
hemolytic uremic syndrome (HUS). All STEC produce one or both of two Shiga toxins,
Stx1 and Stx2. STEC strains that produce Stx2 are more strongly associated with HUS
than strains that produce Stx1 or both Stx1 and Stx2. Epidemiologic evidence indicates a
recent increase in the rate of HUS among STEC outbreaks. The increasing rate of HUS
could be explained by a shift in the toxin profiles of STEC strains. The purpose of this
study was to examine trends in toxin profiles of human STEC O157 isolates from 1996 to
2008 and to assess whether an increase in the number of Stx2-only-producing strains
could be correlated with a recent increase in HUS cases. Data from three independent
datasets, collected from PulseNet, eFORS and NARMS, were used. Additionally, trends
such as seasonal variations, geographical variations, gender differences, and age
differences were examined for each toxin profile. Results from this study show a shift in
the toxin profile of human STEC O157 strains in the United States, in that the proportion
of Stx2-only producing strains has increased dramatically since 1996.

INDEX WORDS: E. coli O157:H7, Shiga toxin-producing E. coli (STEC), Hemolytic
Uremic Syndrome (HUS), Shiga Toxin
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CHAPTER I: INTRODUCTION
Background:
Escherichia coli are a group of bacteria whose members are typically nonpathogenic normal microflora of the intestinal tract of humans and animals. However,
certain strains of this bacterial species have acquired genes that enable them to cause
intestinal disease. The E. coli that cause enteric disease have been divided into pathotypes
based on their virulence factors and mechanisms by which they cause disease. One of
these pathogens, called Shiga toxin-producing E. coli, refers to those strains of E. coli
that produce at least one member of a class of potent cytotoxins called Shiga toxins
(Gyles 2006).
During the past two decades, an increasing number of human foodborne illness
outbreaks have been traced to consumption of undercooked ground beef and other beef
products contaminated with Shiga toxin-producing Escherichia coli O157 (STEC).
STEC, also referred to as Verocytotoxin-producing E. coli (VTEC) are causes of major,
potentially fatal, zoonotic food-borne illness whose clinical spectrum includes diarrhea,
hemorrhagic colitis, and hemolytic uremic syndrome (HUS) (Karmali 2003). STEC
infections are considered a public health problem in both developed and developing
countries because of the severity of the disease they cause and the global nature of the
food supply (Brando 2008).
Shiga toxin-producing Escherichia coli (STEC) is a major cause of foodborne
illness in the United States, and is usually acquired by ingestion of contaminated food or
water, contact with animals, or by person-to-person transmission. Sources of STEC
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infection in humans include foods of animal origin such as meats (especially ground
beef), unpasteurized milk, and other vehicles that have been contaminated with STEC,
such as fresh-pressed apple cider, yogurt, and vegetables such as alfalfa sprouts, lettuce,
and other leafy greens. Waterborne transmission and contact with infected animals are
two routes of transmission that are becoming increasingly recognized. In addition to
large, widespread outbreaks in the United States, outbreaks of STEC infection have been
documented in at least 14 countries in a variety of settings, including households, daycare
centers, schools, restaurants, nursing homes, and prisons (Karmali 2003).
STEC causes severe gastroenteritis and may cause life-threatening HUS, the most
serious complication of STEC infection. Most patients with HUS in developed countries
have evidence of exposure to Shiga toxin-producing E. coli (O'Brien 1998). HUS is a
leading cause of acute renal failure in children and occurs in about 6% of patients with
STEC infection (Griffin 1998). Up to 40% of patients with HUS develop long-term renal
dysfunction and about 3-5% of patients die during the acute phase of the disease (Karmali
2003).
Although the main virulence factor of STEC is the production of one or more type
of Shiga toxin (Stx1, Stx2, or both), adherence to the intestinal epithelium and
colonization of the gut are also important components of the disease. Although STEC is
not typically invasive and is restricted to the lumen of the gut, in some circumstances
Shiga toxin (Stx) produced within the intestinal tract is able to cross the epithelial border
and enter the bloodstream. Both Stx1 and Stx2 are capable of crossing epithelial borders
via an energy-requiring process, and the toxin that moves across the border retains its
biological activity. Stx targets the endothelium of susceptible tissues, resulting in

3
intestinal as well as systemic dysfunction (Brando 2008). While the route that the toxin
uses to pass across epithelial cell barriers is not well understood, it appears to take a
transcellular route. This notion is based on the observation that toxin movement is energy
dependent and directional, with greater toxin movement in the apical-to-basolateral
direction than vice versa (Acheson 1998).
Molecular subtyping, such as pulsed-field gel electrophoresis (PFGE), is critical
in linking widely dispersed outbreaks of STEC. Subtyping can link seemingly sporadic
cases so that a vehicle can be implicated and public health officials and consumers can
advocate for changes to make food safer. Molecular subtyping has had several major
impacts on public health, including increasing the ability to identify outbreaks that would
otherwise be missed, increasing the specificity of the definition of outbreaks, and
allowing outbreaks to be detected and controlled at an earlier stage (Tauxe 2006).
To facilitate epidemiologic investigations, the Centers for Disease Control and
Prevention (CDC) established a national molecular suptyping network for foodborne
disease surveillance in the United States, known as PulseNet. Since its inception in 1996,
PulseNet has been instrumental in the detection, investigation, and control of numerous
outbreaks caused by STEC and other foodborne disease-causing bacteria. A server
housed at the CDC holds a national database of STEC isolates submitted by state and
local health departments in the United States. By rapidly detecting clusters of STEC
infections, the E. coli national database is a key tool in the recognition and investigation
of outbreaks (Gerner-Smidt 2006).
Additionally, since 1973, CDC has maintained a collaborative surveillance
program for collection and periodic reporting of data on the occurrence and causes of
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foodborne-disease outbreaks (FBDOs) in the United States. The Foodborne Disease
Outbreak Surveillance System reviews data on FDBOs, defined as the occurrence of two
or more cases of a similar illness resulting from the ingestion of a common food. State
and local public health departments have the primary responsibility for identifying and
investigation FDBOs. These departments use a standard form to report these outbreaks.
Since 2001, reports of FDBOs are submitted through a web application on the internet
called the Electronic Foodborne Outbreak Reporting System (eFORS) (Lynch 2006).
In 2007 the eFORS system began undergoing developmental changes, and will soon be
replaced by the National Outbreak Reporting System (NORS). While eFORS collects
outbreak data on foodborne outbreaks, NORS will integrate foodborne, waterborne,
zoonotic, and person-to-person enteric disease outbreaks. It is estimated that NORS will
be deployed in early 2009 (Ayers 2008).

Study Rationale:
The motivation for this study comes from an observed increase in the number of
E. coli O157:H7 outbreaks in the United States population and the increased rate of HUS
within these outbreaks. Epidemiologic evidence in Europe shows a recent increase in the
rate of HUS among cases involved in STEC outbreaks (Werber 2003). The increasing
rate of HUS could be explained by a shift in the toxin profiles (Stx1, Stx2, and Stx1+2) of
STEC strains.
The purpose of this study is to examine trends in toxin profiles (Stx1, Stx2, or
both) of human STEC O157 isolates from 1999 to 2008 and to assess whether an increase
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in the number of Stx2-producing strains is correlated with the recent increase in HUS
cases in outbreaks.

Research Questions:
From initial observations and review of the literature, the following research
questions were formulated:
1) Has there been an increase in the number of STEC O157:H7 outbreaks within
the time period observed (1999-2008)? If so, what factors could be affecting these
numbers?
2) Has there been an increase in the number of STEC O157:H7 strains that
produce Shiga toxin 2-only within the time period observed (1999-2008)? If such
an increase exists, have there been any changes in toxin testing practices?
3) Has there been an increase in the rate of HUS among STEC outbreaks
occurring in the United States from the time period observed (1999-2008)?
4) Are there any other observable trends in the number of STEC O157:H7
outbreaks and HUS rates within the time period observed (1999-2008), including
demographic, seasonal, or geographic trends?
5) Could trends in HUS rates be due to shifts in the toxin profiles produced by
STEC O157:H7 strains?
6) Are certain PFGE patterns associated with certain toxin profiles in STEC
O157:H7 strains?
7) Are certain toxin profiles associated with non-O157 STEC strains?
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Hypotheses:
The following hypotheses were generated from the questions proposed, general
observations, the literature reviewed, and the data collected:
1) HO: There has not been a change in the number of foodborne outbreaks caused by
STEC O157:H7 reported during the time period of 1999-2008.
HA: There has been an increase in the number of foodborne outbreaks caused by
STEC O157:H7 reported from the time period of 1999-2008.
2) HO: There has not been a relative increase in the number of STEC O157:H7
strains that produce Shiga toxin 2-only from the time period of 1999-2008.
HA: There has been a relative increase in the number of STEC O157:H7 strains
that produce Shiga toxin 2-only from the time period of 1999-2008.
3) HO: There has not been an increase in the rate of HUS among STEC O157
outbreaks reported in the United States from the time period observed (19992008).
HA: There has been an increase in the rate of HUS among STEC O157 outbreaks
in the United States from the time period observed (1999-2008).
4) HO: There are no other observable trends in the number of STEC O157:H7
outbreaks and HUS rates within the time period observed (1999-2008), including
demographic, seasonal, or geographic trends.
HA: There are other observable trends in the number of STEC O157:H7 outbreaks
and HUS rates within the time period observed (1999-2008), including
demographic, seasonal, or geographic trends. Trends in age and gender include
higher rates of STEC O157:H7 infections among young children (<5 years of age)
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and those of female gender. STEC O157:H7. Seasonal trends include higher rates
of STEC O157:H7 infection in summer and fall months, for each toxin type.
Geographic trends include higher concentrations of STEC O157:H7 cases in midwestern and mountain states.
5) HO: PFGE patterns do not correlate with the toxin profile of STEC O157:H7
strains.
HA: PFGE patterns correlate with the toxin profile of STEC O157:H7 strains.
6) HO: Non-O157 STEC strains are not more likely to be associated with the toxin
profile Stx1-only than the other two toxin profiles.
HA: Non-O157 STEC strains are more likely to be associated with the toxin
profile Stx1-only than the other two toxin profiles

CHAPTER II: LITERATURE REVIEW

Public Health Significance of STEC O157:H7 Infections
The occurrence of massive outbreaks of STEC infection, especially resulting
from the most common serotype, E. coli O157:H7, and the risk of developing HUS, the
leading cause of acute renal failure in children, make STEC infection a public health
problem of serious concern (Karmali 2003). Since the first outbreak caused by E. coli
O157:H7 in 1982, this agent has emerged as a foodborne pathogen leading to
hemorrhagic colitis (HC), hemolytic uremic syndrome (HUS) and thrombocytopenic
purpura (TTP) (O'Brien 1998). The main virulence factor of STEC is the production of
one or more type of Shiga toxin, (Stx1, Stx2, or both).
Recent epidemiologic evidence indicates that the incidence of infections with
STEC O157:H7 and other strains has increased in the 1980s and 1990s. In 1999, it was
estimated that STEC O157:H7 causes approximately 73,000 illnesses and 61 deaths
annually in the United States (Mead, 1999). The Foodborne Diseases Active Surveillance
Network (FoodNet) of CDC's Emerging Infections Program collects data from 10 states
regarding diseases caused by pathogens commonly transmitted through food. FoodNet
quantifies and monitors the incidence of these infections by conducting active,
population-based surveillance for laboratory-confirmed infections. In 2007, 545 cases of
STEC O157 were identified in FoodNet surveillance areas, yielding an incidence of 1.20
cases per a population of 100,000 with large geographical variation. The highest
incidence for STEC O157 infections was among children aged <5 years (3.66 cases per a
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population of 100,000). In 2006, FoodNet identified 82 cases of post-diarrheal HUS in
persons aged <18 years (0.78 cases per 100,000 children); 58 (0.7%) cases occurred in
children aged <5 years (2.01 cases per 100,000 children). Table 1 shows the 2007
incidence of laboratory-confirmed STEC O157 infections and post-diarrheal HUS by
FoodNet site, as compared to the Healthy People 2010 Objective for food safety (CDC
2008).

Table 1: Incidence* of laboratory-confirmed bacterial and parasitic infections in
2007 and post-diarrheal hemolytic uremic syndrome (HUS) in 2006, by site and
pathogen, compared with national health objectives┼. Source: MMWR 2008.
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The relative rates of laboratory-confirmed infections of STEC O157 and other foodborne
pathogens (Campylobacter, Listeria, Salmonella, and Vibrio) from 1996-2007 according
to data collected by FoodNet is shown in Figure 1.

Figure 1: Relative rates of laboratory-confirmed infections with Campylobacter,
STEC* O157, Listeria, Salmonella, and Vibrio compared with 1996-1998 rates, by
year. Foodborne Diseases Active Surveillance Network, United States, 1996-2007┼.
Source: MMWR 2008.

Vibrio

Salmonella
STEC O157
Campylobacter
Listeria

Although significant declines in the incidence of certain foodborne pathogens
have occurred since 1996, these declines mainly occurred before 2004. Declines in the
incidence of STEC O157 infections in 2003 and 2004 have not been maintained.
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Although the United States Department of Agriculture Food Safety and Inspection
Service (USDA-FSIS) and the beef processing industry have implemented interventions
to reduce ground beef contamination, 21 beef product recalls for possible contamination
with STEC O157 were issued in 2007, of which 10 were illness associated, an increase
compared to previous years. USDA-FSIS launched an STEC O157 initiative in fall 2007
and hosted a public meeting in spring 2008 to explore solutions to the challenges the
pathogen presents (CDC 2008).

Shiga Toxin Nomenclature and Verotoxins
In 1898, Kiosha Shiga described the agent of epidemic bacterial dysentery,
Shigella dysenteriae type 1 (Shiga’s bacillus). Shiga’s bacillus was later found to produce
Shiga toxins. In 1972, Keusch and colleagues found that Stx alone caused fluid
accumulation and enteritis in rabbit intestines, revealing that Stx can contribute to bloody
diarrhea. In 1977, Konowalchuck and colleagues made the critical finding that certain
diarrheagenic E. coli stains make a cytotoxin that can kill Vero cells (cells derived from
the kidney epithelial cells of the African green monkey), hence the name verotoxin. In
1983, O’Brien and colleagues reported that a Shiga-like toxin was produced by the E. coli
O157:H7 strain that had caused an outbreak of hemorrhagic colitis in the United States,
and that this toxin was the same as the verotoxin produced by E. coli O157:H7. Thus, in
1983, the paths of research on Shiga toxins and verotoxins merged. Following these
significant findings, the mid to late 1980s heralded the era of the molecular
characterization of the genes encoding the Stx family members and it was shown that the
Shiga toxin from Shigella dysenteriae belonged to the Shiga toxin type (O'Brien 1998).
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Two main categories of Shiga toxins have been distinguished, E. coli Shiga toxin 1 (Stx1)
is almost identical to the Shiga toxin of Shigella dysenteriae in amino acid sequence,
whereas Shiga toxin 2 (Stx2) is less related to the Shiga toxin of Shigella and is not
neutralized by antibodies to either Stx1 or Shiga toxin from S. dysenteriae (Boerlin
1998).

Human Illness
In outbreaks of STEC O157:H7, the mode of transmission is most often food,
followed by animal contact, person-to-person spread, recreational water, and drinking
water. STEC infection typically occurs in the summer and fall and mostly affects young
children, but the elderly also have an increased risk of infection. The infectious dose is
very low, estimated to be less than 100 to a few hundred organisms (Griffin 1998). The
sequence of events of STEC O157:H7 infection begins with the ingestion of the
organism, followed typically by a 3-4 day incubation period while it colonizes the large
bowel and multiplies. Illness then begins with non-bloody diarrhea and abdominal
cramps. Most persons who come to medical attention develop bloody diarrhea, typically
in the 2nd or 3rd day of illness. Illness usually resolves within a week, but in about 6% of
patients HUS occurs. Fever and vomiting are not prominent features (Griffin 1998).
Approximately 10% of patients with STEC O157:H7 infections do not experience bloody
diarrhea, however, patients with non-bloody diarrhea have the same risk of developing
HUS as do patients with hemorrhagic colitis, and they are as severely affected in terms of
abdominal pain and other symptoms (Tarr 1998). Figure 2 illustrates the range in
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symptomatology of STEC disease from asymptomatic infection to death, and the
potential symptoms along its progression.

Figure 2: STEC O157 pathway of disease. Source: STEC – Role of Clinical and
Public Health Microbiologists in Testing and Outbreak Situations. Source: STEC –
Role of Clinical and Public Health Microbiologists in Testing and Outbreaks.
Presented by Dr. Peter Gerner-Smidt, 108th ASM General Meeting, Boston 2008
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Animal Illness
Healthy dairy and beef cattle are the major reservoir of a diverse group of STEC
that infects humans through contamination of food and water, as well as through direct
contact (Gyles 2006). Naturally acquired STEC infections have also been detected in a
wide spectrum of animal species (sheep, goat, deer, moose, swine, horse, dog, cat,
pigeon, chicken, turkey). Several of these animal hosts, particularly ruminants, have been
identified as major reservoirs of STEC strains that are highly virulent in the human host,
including STEC O157:H7 (Wieler 2003) .
However, in contrast to the human host, most STEC infections of animals remain
clinically inapparent. Even in ruminant species, where high shedding rates have been
reported, the clinical significance of STEC infections appears to be rather limited. Calves
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are infected soon after birth through fecally contaminated milk and surroundings. Studies
show that STEC O157 strains are only pathogenic for animals younger than 3 weeks, a
finding pointing toward a possible age-dependent expression of STEC-specific intestinal
receptors in animals. Similar to the diagnostic approach in human STEC infection, a
definitive diagnosis in animals is based on the isolation of the bacteria from fecal
specimens and subsequent confirmation by the demonstration of virulence factors or their
genes (Wieler 2003).

Hemolytic Uremic Syndrome (HUS)
HUS, which was first described in 1955 by Gasser et al. in Switzerland, is defined
by a triad of clinical features that include renal failure, thrombocytopenia, and
microangiopathic hemolytic anemia. Before 1983, most nephrologists thought HUS was a
multifactorial disease that could result from a number of initiating events. Because HUS
occasionally occurred in outbreaks, an infectious agent was sought. The strongest
documented linkage between HUS and a microorganism was the association of Shigella
dysenteriae type 1. Several studies had noted that many, if not the majority, of HUS cases
were preceded by diarrhea. The key event in the linkage of HUS and STEC was the
report by Karmali et al. in 1983 that sporadic cases of HUS were linked to the presence of
Stx and/or E. coli that produced Stx in patients’ stools. This initial report was confirmed
by a prospective controlled study that linked cases of HUS with isolation from the stools
of patients with STEC infections belonging to at least 6 different O serogroups (O26,
O111, O113, O121, O145, and O157). Subsequent reports also noted an association
between STEC and post-diarrheal TTP, a syndrome more commonly found in adults that
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shares many features of HUS (O'Brien 1998). The development of HUS is thought to be
related to the translocation of Stx into the bloodstream, although the precise mechanism
for this is unknown (Karmali 2003).
The severity of HUS varies from an incomplete or mild clinical picture to severe
and fulminating disease with multiple organ involvement, including the bowel, heart,
lungs, pancreas, and central nervous system (Karmali 2003). Neurological complications
such as seizures, stroke, cerebral edema, or coma may occur in HUS, but there is little
information on the pathophysiology of the central nervous system (O'Brien 1998).
Approximately two-thirds of children with HUS require dialysis, and about one-third
have milder renal involvement without the need for dialysis. The use of anti-motility
agents and antibiotics, having bloody diarrhea, fever, vomiting, elevated serum leukocyte
count, being of a young age (<5 years) and of female gender have been associated with
increased risk for HUS following STEC infection in some studies (Scheiring 2008).
HUS has been reported to occur with a frequency of about 8% in several
outbreaks of E. coli O157:H7, although in one outbreak among elderly nursing home
residents, it was as high as 22%. Recently, a large, well-publicized multistate outbreak
associated with fresh spinach consumption occurred in September 2006 across 26 states
with approximately 200 illnesses and 3 deaths. The HUS rate for this outbreak was found
to be 15.6% (CDC 2006).
The incidence of HUS in North America is about three cases per 100,000 children
under 5 years of age per year; the rate among older children is somewhat lower, and the
rate among adults is not known (Mahon 1997). This is in contrast to a roughly 10-fold
higher incidence (consistently) in children under 5 years of age in Argentina. In South
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Africa and the US, HUS appears to be more common in white than in black children. In
Argentina, HUS occurs more commonly in upper-income than in lower-income groups.
Reasons for these differences are unknown (Karmali 2003).

Treatment and Prevention
In an outbreak setting, rapid diagnosis of cases and immediate notification of
health authorities is essential for effective intervention. The presentation to medical care
of a child with definite or possible E. coli O157:H7 infection but before HUS ensues
affords a potential opportunity to ameliorate the course of subsequent renal failure. HUS
can be categorized as either oligoanuric (which probably signifies acute tubular necrosis)
or nonoligoanuric. Children with oligoanuric renal failure during HUS generally require
dialysis, have more complicated courses, and are probably at increased risk for chronic
sequelae than are children who experience nonoligoanuric HUS (Ake 2005). A
prospective study on 29 children with HUS that was confirmed microbiologically to be
caused by E. coli O157:H7 was performed by Ake et al. This study found that early
recognition and parenteral volume expansion during E. coli O157:H7 infections, well
before HUS develops, is associated with attenuated renal failure. Parenteral hydration in
children who are possibly infected with E. coli O157:H7, at the time of presentation with
bloody diarrhea and in advance of culture results, is a practice that can accelerate the start
of volume expansion during the important pre-HUS interval. Rapid assessment of stools
for E. coli O157:H7 by microbiologists and reporting of presumptive positives
immediately can alert practitioners that patients are at risk for developing HUS and can
prompt volume expansion in children (Ake 2005).
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The use of antibiotics to treat patients with STEC infection has been quite
controversial. Most clinicians experienced in the management of STEC infections in the
US and Canada have found that antimicrobial agents have little clinical effect and
occasionally seem to increase the chances of HUS, however this finding is still in debate.
A less controversial treatment that is being followed is the use of Synsorb-Pk, which is an
investigational new drug that has been promoted as safe and effective for the treatment of
HUS in children infected by E. coli. This drug is intended to absorb the toxin in the
intestine before it reaches the bloodstream. There have been improvements in the
treatment of renal failure, however the biggest challenge facing clinicians is to develop
interventions to prevent renal involvement (O’Brien 1998).
Another area of investigation is the development of vaccines against STEC.
Successful vaccination of pigs against edema disease, using Stx2e toxoids, (bacterial
toxins whose toxicity has been weakened or suppressed by chemical or heat treatments),
offers hope for human vaccines (O’Brien 1998). Anti-Shiga toxin antibodies have been
shown to prevent HUS in animals. In December 2005, the US Food and Drug
Administration (FDA) approved orphan drug status for two chimeric anti-Shiga toxin
antibodies (caStx1 and caStx2, made by Caprion Pharmaceuticals, Inc.) in the treatment
of STEC infections. The antibodies are intended to neutralize circulating Stx1 and Stx2,
thereby preventing serious complications such as bloody diarrhea, destruction of red
blood cells and platelets, and HUS. The product is being evaluated for preventing HUS in
a dose-escalating, phase 1, US clinical trial of STEC infected pediatric patients (Scheiring
2008).
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Detection and Isolation of STEC
Timely and accurate diagnosis of STEC infections is extremely important from
both a public health and a clinical management perspective. Several days may occur
between the point at which the patient is exposed to the pathogen and when he/she is
included as a case in an outbreak. These include the time it takes for the patient to
become ill after ingesting the contaminated food (3-4 days), the time it takes for the
patient to contact the healthcare system (1-5 days), the time it takes to diagnose the
infection after a stool sample is collected (1-3 days), the time it takes for the patient’s
specimen to be shipped from the clinical laboratory to the public health laboratory (1-7
days), and the time it takes for the public health laboratory to perform molecular testing
on the patient’s specimen to confirm the case as part of an outbreak (2-10 days). In cases
of HUS, the typical clinical signs usually become apparent within two weeks after the
onset of gastrointestinal (GI) symptoms, by which time the numbers of the causative
STEC may be very low, or diarrhea may no longer be present.
For these reasons, STEC detection methods need to be very sensitive. Diagnostic
methods are based on the detection of the presence of either Stx genes in fecal extracts or
fecal cultures and/or isolation of the STEC itself. These procedures differ in complexity,
speed, sensitivity, specificity, and cost, therefore diagnostic strategies must be tailored to
the clinical circumstances and resources available (Paton J. 2003). Culture on SorbitolMacConkey agar (SMAC) or the more selective cefixime and tellurite sorbitolMacConkey (CT-SMAC) agar has been the most commonly used method for isolation of
STEC O157. This is because unlike the majority of fecal E. coli strains, most O157:H7
and O157:H- STEC are unable to ferment sorbitol. SMAC or CT-SMAC plates are
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inoculated with the fecal specimen and examined after 18-24 hours of incubation for the
presence of colorless, sorbitol-negative colonies. Individual colonies can then be tested
by slide or tube agglutination with commercially available O157-and H7-specific antisera
or latex reagents (Paton A. 2003). Although screening fecal cultures on SMAC or CTSMAC is inexpensive and involves minimal labor and equipment, it is serotype-specific
in that it will only detect STEC O157.
Immunomagnetic separation (IMS) is a powerful concentration technique for the
isolation of STEC from low-abundance specimens. This procedure involves coating
magnetic beads with anti-LPS (lipopolysaccharide) and mixing them with broth cultures
or suspensions of feces or food samples. The beads and bound bacteria are then trapped
in a magnetic field, any unbound suspension is decanted, and the beads are washed. After
additional binding and washing cycles, the beads are plated and the resultant colonies are
tested for Shiga toxin production. IMS is an extremely valuable technique in
circumstances where deliberate targeting of STEC O157 is justifiable, such as for
analysis of food samples that have been epidemiologically linked to human cases of
STEC, and for analysis of stool cultures from patients with HUS (Paton A. 2003). IMS is
also valuable for detection of the most common non-O157 STEC serotypes for which
antibodies are available, e.g. O111, O26, O103, and O45.

Shiga Toxins and Adherence to Epithelial Cell Surfaces
Once STEC has been ingested, they are able to survive the acidity of the
stomach in sufficient numbers to colonize portions of the lower GI tract. Once the
organisms are in the lower portion of the intestine, the bacteria adhere to, and interact
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with, the epithelial cell surface by using a variety of virulence factors, some of which are
encoded by genes present on a pathogenicity island (PAI) known as the locus of
enterocyte effacement (LEE). A PAI is a stretch of foreign DNA that is incorporated into
the genome of pathogenic microorganisms and carries genes encoding one or more
virulence factors, including toxins (Figure 3). The GC content of a PAI differs from that
of the rest of the genome, indicating that at some point in history the pathogen has
acquired the DNA located on the PAI from an outside source (Hacker 2000).
Figure 3: Illustration of the LEE pathogenicity island (PAI) within STEC O157
strain. The PAI contains genes which encode various virulence factors for the
organism. Source: STEC – Role of Clinical and Public Health Microbiologists in
Testing and Outbreaks. Presented by Dr. Peter Gerner-Smidt, 108th ASM General
Meeting, Boston 2008
PAI

Nearly all O157 strains contain the E. coli attaching and effacing (eae) gene,
which mediates the attachment to and destruction of the microvilli of the intestinal
epithelial cells (Bulte 2003). Once the organism adheres to the epithelial cell surface, it
then produces Shiga toxins, which are capable of causing damage both locally and
systemically (Acheson 1998). Figure 4 illustrates this component of STEC pathogenesis.
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Figure 4: Adherence of STEC O157 bacteria to intestinal epithelial cell and delivery
of Shiga toxin inside the cell. Source: Nataro and Kaper, 1998. Clinical
Microbiological Review 11: 142-201.

It is well established that certain patients develop endothelial cell damage in sites
that are at a distance from the GI tract following infection. This is thought to be due, to
some degree, to the direct action of the toxins (Acheson 1998). Shiga toxin is toxic to
cells at picomolar concentrations, and they are among the most potent biological
substances known (Karmali 2003).
The toxins share a polypeptide subunit structure consisting of an enzymatically
active A-subunit that is linked to a pentamer of B-subunits. The A-B subunit structure
binds to a specific receptor on the surface of eukaryotic cells (Nataro and Kaper 1998).
Figure 5 illustrates the structure of the toxin. After binding to a receptor on the eukaryotic
cell, the toxins are internalized by endocytosis. Once inside the cell, the A subunit is split
and becomes activated, and the toxins target the endoplasmic reticulum by a process
called “retrograde transport”, where they interact with subcellular components, resulting
in the inhibition of protein synthesis and cell death. Although the endothelial cell appears
to be the main target for Stx action, there is evidence that the toxins may also mediate
biological effects by interacting with other cell types such as renal tubular cells and
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monocytes (Karmali 2003). Endothelial cell damage is central to the pathogenesis of
HUS, and damage is normally caused in the renal cells, but may also occur in the gastrointestinal tract, as well as other organs including the pancreas, lungs, and brain.

Figure 5: The toxin has two subunits, designated A and B. The B subunit is a
pentamer that binds to specific glycolipids on the host cell, specifically
globotriaosylceramide (Gb3). Source: STEC – Role of Clinical and Public Health
Microbiologists in Testing and Outbreaks. Presented by Dr. Peter Gerner-Smidt,
108th ASM General Meeting, Boston 2008
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Differences in Toxin Types
Two types of Shiga toxins exist: Stx1 and Stx2. Some studies have suggested that
STEC strains producing Stx2 may be more closely associated with severe disease and
HUS than strains producing Stx1-only. In a study from the United States, patients
infected with STEC O157 possessing Stx2 but not Stx1 were significantly more likely to
develop systemic sequelae, including HUS, than were patients infected with STEC O157
harboring Stx1 alone or Stx1 and Stx2 (Ostroff 1989).
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In 2004, Ethelberg et al. conducted an analysis of strain and patient factors
associated with the development of bloody diarrhea and HUS among STEC patients
registered in Denmark in a 6-year period. This study found that a major risk factor for
bloody diarrhea and HUS was the presence of the Stx2 and eae genes (Ethelberg 2004). A
study conducted in 1999 by Boerlin et al. revealed a strong statistical association
(OR=4.95; p=0.0038) between the Stx2 gene and severity of disease for a set of 112
human isolates from eight major serotypes (Boerlin 1999).
One possible explanation for this is that Stx2 moves across the intestinal epithelial
cell barrier to a greater extent that does Stx1. One study found that Stx1 binds with higher
affinity than Stx2 in a number of epithelial and endothelial cells. One speculation is that
if Stx1 is binding to many of the available receptors with higher affinity, it may be more
likely to be “held up” in the intestine, preventing it from entering the bloodstream. It is
not clear if Stx1 and Stx2 are moving across the intestinal epithelial cells via the same
pathway, although it is highly probably that they are (Acheson 1998). Each Stx type may
be present alone or in combination in STEC. The pathogenicity of STEC infection in
humans depends on many bacterial virulence factors including among others, Stx,
enterohemolysin, intimin (encoded by the eae gene), and host factors such as age.

Toxin Subtypes
Each Stx type (Stx1 and Stx2) may be further divided into several subtypes. For
example, Stx1 may be divided into 4 subtypes, Stx1a, Stx1b, Stx1c, and Stx1d, and Stx2
may be divided into 7 subtypes, Stx2a-g. Stx2e typically is associated with pig edema
disease and has been rarely detected in STEC of human origin (Friedrich 2002). The
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Stx2a subtype is also called the Stx2 subtype by some investigators, in order to avoid
confusion with the A subunit of the toxin.
The Stx subtype may be associated with the clinical presentation and severity of
illness among STEC infections. A number of studies have documented that types Stx2a
and Stx2c are more often associated with HUS than the other Stx2 subtypes, but Stx2d
and Stx2e-containing strains have also been isolated from humans with HUS. These data
suggest that some Stx2 subtypes augment the ability of STEC to cause serious human
disease (Friedrich 2002). Polymerase Chain Reaction- Restriction Fragment Length
Polymorphism (PCR-RFLP) has been the preferred tool for subtyping Stx2 genes. This
method is, however, vulnerable to single-nucleotide changes and is difficult to interpret if
the strain contains more than one subtype or if the fragments generated are small or of
similar sizes (Persson 2007). Figures 6 and 7 illustrate the similarity of the different
subtypes of each toxin type, Stx1 and Stx2, and how certain STEC serotypes group
among the subtypes of each type. These dendrograms are amino acid sequences
translated from the partial sequences of the Stx1 and Stx2 genes.
Figure 6: Stx1: 4 subtypes (Stx1a-d); 7 variants. Source: F. Scheutz, USDA, FDA,
CDC: Public non-O157 meeting, Washington DC 2007.
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Figure 7: Stx2:7 subtypes (Stx2a-g); 35 variants
Source: F. Scheutz, USDA, FDA, CDC: Public non-O157 meeting, Washington DC
2007.
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STEC Serotypes
Serotyping is an important basis for differentiating STEC and is often the starting
point in the characterization of STEC strains. The serotype of an E. coli isolate is based
on the O-antigen determined by the polysaccharide portion of cell wall
lipopolysaccharide (LPS), and the H antigen due to flagella protein. There are 174 Oantigens and 53 H-antigens (Scheutz 2004) described so far in the international
serotyping scheme, with E. coli isolates having various combinations of O and H
antigens. A high percentage of STEC serotypes are nonmotile (NM) mutants of strains
without an H antigen, but these strains are capable of causing illness as severe as STEC
O157:H7 (Gyles 2006).
Severe disease and outbreaks are most commonly due to serotype O157:H7.
Because of the importance of serotype O157:H7 in human disease and the ease in which
STEC infections are detected and diagnosed, it is common to consider STEC serotypes in
two major categories: O157 and non-O157. The most widely used methods for isolating
STEC O157 are serotype and sorbitol fermentation specific and do not detect non-O157
strains. For this reason, the number of documented infections with STEC strains other
than non-sorbitol-fermenting STEC O157 is underestimated (Strockbine 1998).
STEC strains are often considered as a group but there may be important
differences between serotypes. Different serotypes may have differences in clinical
features. Non-bloody diarrhea is more commonly reported among persons infected with
non-O157 strains. Isolates from blood and urine are also more commonly seen among
persons with non-O157 infections, therefore the spectrum of illness with non-O157 STEC
may be wider than that for O157.
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E. coli O157 seems to be the predominant serotype of STEC in the US, Canada,
the UK, and Japan, but in continental Europe, Latin America, and Australia, non-O157s
are much more common. However, the clinical presentation is not independently related
to the serotype. Rather than the serotype or O group, the combined presence of the eae
and Stx2 genes is an important predictor of HUS (Ethelberg 2004).
With the introduction of diagnostic methods targeting Stx or the Stx genes, more
non-O157 infections are now being diagnosed in all countries, including the United
States, Canada, the UK, and Japan. In Germany, where STEC infection is statutorily
notifiable regardless of serotype, non-O157 STEC infections account for almost 80% of
reported gastroenteritis cases, and approximately a third of STEC-associated HUS cases
(Frank 2008). In addition to STEC O157:H7, other serotypes that have caused major
outbreaks in the United States include O26:H11, O103:H2, O111:H-, O111:H8, O121:H-,
and O145:H- (Bulte 2003). Table 2 provides the toxin profiles of fifteen of the most
prevalent non-O157 STEC serotypes isolated from humans in the United States during
1983-2002.
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Table 2: Toxin profiles and virulence factors of most prevalent non-O157 STEC
serotypes isolated from humans, United States, 1983-2002. Source: Brooks et al.
Journal of Infectious Diseases 2005: 192; 1422-1429

Molecular Subtyping and PulseNet
In order to investigate the relatedness of STEC strains isolated from outbreaks or
sporadic cases, the gold standard method of strain typing that is used is pulsed-field gel
electrophoresis (PFGE). PFGE is a Restriction Fragment Length Polymorphism (RFLP)
method that uses restriction enzymes to generate a relatively small number of large DNA
fragments. Such fragments are too large to separate by conventional electrophoresis but
can be separated when subjected to a changing (pulsed) electrical field. The greatest
difficulty in interpreting PFGE results comes in deciding whether or not patterns are
indistinguishable. Such difficulties in interpreting subtyping results should serve as a
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reminder that subtyping is an adjunct to, not a replacement for, a thorough
epidemiological investigation (Strockbine 1998). For STEC O157 strains, restriction
enzymes XbaI and BlnI are used as the primary and secondary enzymes, respectively
(Figure 8).
Figure 8: PFGE Gel Image of STEC O157 Isolates Restricted with XbaI (lanes 2 and
3) and BlnI (lane 5); Molecular Size Standard Salmonella Braenderup in lanes 1, 4,
and 6. Source: PulseNet E. coli national database, 2009

PFGE has worked effectively to identify STEC isolates from multiple cases that
were epidemiologically related (Watanabe 2003). Subtyping is critical in linking cases in
widely dispersed outbreaks. The role of subtyping is illustrated by the investigation of
clusters of O157 infections in June and July 1997 that occurred hundreds of miles apart in
Virginia and Michigan. Among the 70 ill persons identified, 97% had bloody diarrhea
and 51% were hospitalized. Independent investigations linked both outbreaks to alfalfa
sprouts. Strains from patients in the two states were compared and revealed
indistinguishable PFGE patterns. Traceback of seeds from which the sprouts were grown
revealed that they had only been shipped to these two states; all remaining seeds were
removed from the market.
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Subtyping has been an important adjunct to many other outbreaks of O157
(Griffin 1998). In the spinach outbreak in 2006, PFGE linked 183 cases in 26 states
(CDC 2006). In an outbreak in 2007, PFGE linked 38 cases in 8 states to contaminated
ground beef, resulting in a recall of 21.7 million pounds of ground beef products. Also in
2007, PFGE was used to link 21 cases in 10 states to frozen pepperoni pizza, resulting in
a voluntary recall by the company. In 2008, PFGE was used to detect an outbreak
involving 14 cases associated with a daycare center, 36 cases exposed to contaminated
iceberg lettuce served at a university, an outbreak involving 17 cases associated with a
college event, and an outbreak of 66 cases from 8 states associated with ground beef from
a major supermarket chain, among many others.
To facilitate epidemiologic investigations, the Centers for Disease Control and
Prevention (CDC), established a National Network for Molecular Subtyping for
Foodborne Disease Surveillance called PulseNet in 1996. Since its inception in 1996, it
has been instrumental in the detection, investigation, and control of numerous outbreaks
caused by STEC O157:H7, Salmonella enterica, Listeria monocytogenes, Shigella spp.,
and Campylobacter. The PulseNet network is now being replicated in different ways in
Canada, Europe, the Asia Pacific region, Latin America and the Caribbean, and the
Middle East. These independent networks will allow public health officials to share
molecular epidemiologic information in real-time, and will enable rapid recognition and
investigation of multi-national foodborne disease outbreaks (Tauxe 2006).
Public health laboratories use standardized procedures for performance and
interpretation of PFGE and share the data electronically. PFGE is used as the subtyping
method in the network because it is accessible for many laboratories as well as being
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highly discriminatory and reproducible for many pathogens. National databases at the
CDC contain STEC O157 PFGE patterns, as well as other STEC serotypes, which public
health laboratories can access to compare with local PFGE patterns (Swaminathan 2001,
Gerner-Smidt 2006). Sharing of subtyping data on a national level has proved invaluable
in determining the extent of foodborne outbreaks and identifying diffuse outbreaks that
could not be detected by surveillance alone.

Electronic Foodborne Outbreaks Reporting System (eFORS)
Since 1973, the CDC has maintained a collaborative surveillance program for the
collection and periodic reporting of data on the occurrence and causes of foodborne
disease outbreaks (FBDOs) in the US. The Foodborne Disease Outbreak Surveillance
System reviews data on FBDOs, defined as the occurrence of two or more cases of a
similar illness resulting from the ingestion of a common food. State and local public
health departments have primary responsibility for identifying and investigating FBDOs.
State, local, and territorial health departments use a standard form to report these
outbreaks to the CDC. A revised form became available in 1999. The revised form
expanded the range of food items, places, and contributing factors that could be reported
(Lynch 2006).
Since 2001, reports of FBDOs are submitted through a web application on the
internet called the electronic Foodborne Outbreak Reporting System (eFORS). These
reports summarize data collected with both the paper and web-based forms. The majority
of forms are submitted by state, local, and territorial health departments, however, they
can also be submitted by federal agencies and other sources. Reporting officials use
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published criteria to determine whether a specific etiologic agent has been confirmed for
an outbreak and submit reasons that reported food vehicles were implicated (Lynch
2006). In eFORS, data collection after 1998 is considered “Enhanced Surveillance”. Prior
to 1998, about 500 outbreaks per year were reported, and after 1998, the average number
of outbreaks reported increased to 1,250 outbreaks per year (Ayers 2008).

National Outbreak Reporting System (NORS)
In 2007, eFORS began undergoing developmental changes which led to the
development of the National Outbreak Reporting System (NORS). NORS is being
developed by the Division of Foodborne, Bacterial, and Mycotic Diseases (DFBMD) in
collaboration with the Division of Parasitic Diseases, Division of Viral Diseases,
Division of Viral Hepatitis, and National Center for Environmental Health within the
CDC, and is expected to be deployed in 2009. This system will continue to monitor the
overall burden and trends of foodborne diseases, as eFORS, but will integrate the
reporting of foodborne, waterborne, zoonotic, and person-to person enteric disease
outbreaks. NORS data will also be used for human illness attribution studies, which aim
to attribute human cases of illness to specific sources, such as particular food
commodities or animal reservoirs (Ayers 2008).

National Antimicrobial Resistance Monitoring System (NARMS)
The National Antimicrobial Resistance Monitoring System (NARMS) for enteric
bacteria was established in 1996 and is a collaboration between the CDC and the USDA.
Participating health departments forward every twentieth non-Typhi Salmonella isolate,
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every Salmonella Typhi, every twentieth Shigella isolate, and every twentieth E. coli
O157 isolate received at their public health laboratories to the CDC for antibiotic
susceptibility testing. Because NARMS data have been collected continually since 1996,
the data can be used to show trends that provide useful information about patterns of
emerging resistance. Additionally, antimicrobial resistance data from humans provided
by NARMS are important for the development of public health regulatory policy for the
use of drugs in food-producing animals (CDC-NARMS 2008).

STEC in the Food Chain
An area of current exploration concerns how STEC enters the food chain. This
begins with the ecology of STEC in animals and in the environment. An essential
element to the full understanding of E. coli O157:H7 ecology is to determine whether
cattle are typically transiently colonized (subsequently reinfected) or if the microbe is
part of the normal flora and shed only periodically. It is likely that there are non-O157
strains that colonize cattle and do not cause disease in humans, but that cattle nonetheless
are a significant reservoir for human pathogenic non-O157 STEC. One study suggests
that living in a cattle-raising region appears to imply risk not only for STEC O157, but
also for most non-O157 serogroups, and that cattle density is positively associated with
overall STEC incidence (Frank 2008). In addition, some studies suggest that certain
cattle, designated as “supershedders” have greater E. coli O157:H7 transmission potential
than other cattle, whether through greater incidence or persistence of excretion, excretion
of greater concentrations of E. coli O157:H7, or a combination of these factors (Cobbold
2007).
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The USDA-FSIS and beef processing industry have implemented interventions to
reduce contamination of ground beef, and the FDA has approved the use of irradiation of
ground beef in the US. The success of this and other on-the-farm and slaughterhouse
procedures offers promise for reducing meat-borne infections, but an even greater
challenge is to prevent STEC contamination of water and vegetables.
Produce-associated outbreaks accounted for 21% of all foodborne outbreaks of E.
coli O157:H7 from 1982 to 2002. Thirty outbreaks associated with leafy greens have
been reported to the CDC through 2006. With more centralized production and wider
distribution of produce including leafy greens, the propensity for large multistate
outbreaks has increased. Such outbreaks have greatly influenced industry practices and
FDA policy. However, for successful public health interventions to occur, mechanisms of
produce contamination need to be successfully identified and understood (Sodha, 2008).
Additionally, preventing foodborne disease depends in large part on engineering
production systems for safety. Detecting and investigating outbreaks is an important way
to determine the pathways that are most problematic (Tauxe 2006).
Conclusions
The study of the pathogenesis of STEC infections encompasses many different
disciplines, including clinical microbiology, public health, diagnostics, animal ecology,
and food safety, as well as cellular microbiology and the mechanisms of toxin action
(Philpott 2003). This study will attempt to identify trends in the number of foodborne
outbreaks caused by STEC O157 strains in the U.S. during 1999-2008 in addition to
trends in the toxin profiles of those strains and HUS rates of STEC outbreaks. The
number of STEC O157 isolates within the PulseNet national database and their
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corresponding toxin profiles will be compared for each year to identify any existing
trends. Two additional independent datasets, including a dataset collected from eFORS
reports, and a dataset containing a collection of NARMS isolates will be examined for the
same trends, in order to confirm trends observed in the PulseNet dataset. These trends
will be compared to the HUS rates of recent STEC outbreaks in the United States, in an
attempt to identify a direct correlation between an increase in Stx2-only producing strains
and an increase in HUS rates.

CHAPTER III: METHODS
Institutional Review Board Application
The protocol title “Trends in Toxin Profiles of Human O157 Strains Using the
PulseNet E. coli National Database and Electronic Foodborne Outbreak Reporting
System (eFORS), 1999-2008” was approved by the Georgia State University Institutional
Review Board on September 16, 2008. Protocol number is H09100.

Description of Datasets
An isolate is a sample of bacteria retrieved from an infected or contaminated
source. Three independent datasets, each containing Shiga toxin-producing E. coli
(STEC) isolates, were used for this study. These datasets include a collection of STEC
isolates from within the PulseNet E. coli national database, a collection of STEC
outbreaks from eFORS reports, and a random sample of isolates collected by the National
Antimicrobial Resistance Monitoring System (NARMS).

PulseNet Dataset
The PulseNet E. coli national database contains PFGE profiles and toxin
information for E. coli isolates of all serotypes from human and non-human sources.
PulseNet participants (state, county, and city public health laboratories as well as federal
food regulatory agency laboratories and the CDC) subtype all Shiga toxin-producing E.
coli using at least the primary restriction enzyme (XbaI) immediately when they receive
them from diagnostic laboratories. The PFGE profiles (DNA fingerprints) are then
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uploaded to the PulseNet national database along with demographic information (age,
gender, source type, geographic location) of the source. As of December, 2008, the
PulseNet STEC database contained over 35,000 STEC isolates, however the dataset used
in this study contains only human STEC O157 isolates from the USA, uploaded to the
PulseNet database between 1999 and December 15, 2008, for which toxin information is
known, which yielded a sample of 4,402 isolates.
The 4,402 isolates included in this dataset were categorized into three subsets
according to their toxin profile (Stx1-only, Stx2-only, and Stx1+Stx2). The Stx1-only
subset contained 69 isolates, the Stx2-only contained 2,057 isolates, and the Stx1+Stx2
subset contained 2,276 isolates. The number of isolates within each subset was compared
for each year during the time period 1999 to 2008.
In the field of epidemiology, an outbreak is generally defined as the occurrence of
disease that is greater than would otherwise be expected in a particular time and place.
PulseNet identifies clusters, and a cluster is defined as a group of isolates with
indistinguishable PFGE patterns limited in time and occurring at a frequency clearly
above the historical baseline for that PFGE pattern. PulseNet clusters are communicated
to state and CDC epidemiologists for investigation. All communication between PulseNet
participants, epidemiologists, and other stake-holders in outbreak investigations related to
PFGE patterns must be precise. Therefore, PulseNet database managers at the CDC
assign a unique outbreak code to all clusters investigated. In this document, a PulseNet
outbreak is defined as a cluster of isolates that has been given an outbreak code. The
basic code is as follows: (YY)(MM)(LabID)(serotype code of the organism)-(number of
cluster in the month). The first four digits of the outbreak code indicate the year and
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month in which the cluster was detected. The LabID is the two-to four-letter PulseNet lab
identifier for the laboratory that initially recognized the cluster (usually the state postal
abbreviation code). The serotype code of the organism identifies which organism is
involved in the cluster. The digit that follows the organism code denotes the number of
cluster caused by that organism within that month and year in that state (Gerner-Smidt
2006). For example, the PulseNet-assigned outbreak code for the first outbreak of E. coli
O157:H7 seen in January 2009 in Georgia would be 0901GAEXH-1. PulseNet began
assigning outbreak codes in 2002.
Within the PulseNet dataset, toxin profiles were compared for each year of the
time period 1999-2008 for all isolates in the dataset. Then, using the PulseNet-assigned
outbreak code, outbreak isolates were separated from sporadic isolates to determine if
trends were consistent. Those isolates given an outbreak code were considered as
outbreak isolates and those isolates without outbreak codes were considered to be
sporadic. Because outbreak codes were not used in PulseNet until 2002, outbreak and
sporadic isolates were only separated for isolates occurring during 2002-2008.
In the PulseNet dataset, the outbreak code was also used to determine if there had
been an increase in the number of STEC O157 outbreaks from the time period observed.
Using the outbreak code, the number of outbreaks was calculated for each year, for the
time period 2002-2008.

Age and Gender Trends in the PulseNet Dataset
When isolates of STEC O157 are submitted to the PulseNet national database,
certain demographic information relating to the infected patient is linked to the PFGE
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pattern, and both the PFGE pattern(s) and demographic information for an isolate are
submitted to the national database as one entry. The demographic information that is
submitted includes but is not limited to the patient’s age, gender, source site (stool, blood,
etc), and geographical location where the patient’s specimen was collected. Patient and
company names are not submitted to the PulseNet database to protect the privacy of those
individuals and entities.
Using the PulseNet dataset, trends in age and gender distribution were examined
in this study, to determine if certain toxin profiles are more predominantly seen among
certain ages and genders in the population. To determine trends in age distribution, only
isolates submitted with age information were included in this portion of the study.
Likewise, to determine gender distributions, only isolates submitted with gender
information (male or female) were included. The age and gender information was
examined for each of the three toxin profile subsets (Stx1-only, Stx2-only, Stx1+Stx2)
and trends were evaluated for the time period observed.

Seasonal and Geographic Trends in PulseNet Dataset
As previously mentioned, the geographical location where the patient’s specimen
was collected is submitted to the PulseNet national database, and this information may
include the source country, source state, source county, and/or source city. Additionally,
each isolate that is submitted to the PulseNet national database automatically receives a
computer-generated upload date on the date that the isolate was submitted, and this
upload date is linked to the isolate. In addition to the upload date, submitting public
health laboratories may also submit an isolate date (typically the date the specimen was
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received in the clinical laboratory), and a received date (the date the PFGE department in
the public health laboratory received the isolate to perform PFGE on it). Either or both of
these dates (isolate date and received date) may be submitted to the PulseNet national
database when this information is available. An upload date is always available for every
isolate, as it is a computer-generated date that automatically populates the database when
isolates are submitted. In general, there is about one week between the isolate date and
received date, and another week between the received date and upload date; i.e. the
isolate date generally occurs about two weeks prior to the upload date.
In this study, each of the three subsets of toxin profiles were examined for
geographical and seasonal distributions, using the source location (state) and upload date
information available in the PulseNet database. Geographical distributions were mapped
for each toxin profile on a template of the United States. One map was created for each of
the three toxin profiles and showed the geographical distribution of all isolates with that
toxin profile for 1999-2008. Seasonal distributions were identified by graphing the
number of submissions and upload dates (using three-month intervals) for all isolates in
each of the three toxin profile subsets.

Electronic Foodborne Outbreak Reporting System (eFORS) Dataset
The Electronic Foodborne Outbreak Reporting System (eFORS) provided a
second dataset for this study. This dataset was compiled from reports of foodborne
outbreaks and their implicated vehicles submitted to eFORS by state, local, and territorial
health departments, as well as federal agencies. This dataset contained information for
233 STEC O157 outbreaks occurring in the US between 1998 and 2006 and was provided
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by OutbreakNet, the network of epidemiologists at the CDC and in state laboratories
working with foodborne infections. Information within this dataset included (when
available) the reporting state, the estimated number of cases in each outbreak,
transmission type (food, person-to-person, etc), implicated vehicle, number of HUS
cases, number of hospitalized cases, and number of deaths.

HUS Rates in eFORS Dataset
HUS rates were known for 166 (71.2%) of the 233 outbreaks in the eFORS
dataset and were compared for each year during 1998 to 2006 to determine trends. HUS
rates were determined by dividing the number of HUS cases in the outbreak by the total
number of cases in the outbreak in which HUS status was known. The average HUS rate
for all outbreaks was calculated for each year.
Toxin information was only available for 43 (25.9%) of the 166 outbreaks with
known HUS rates. Toxin information is not routinely reported in eFORS, therefore, the
outbreaks in the eFORS dataset were matched to the PulseNet database using as much
information as was available in the eFORS dataset in order to obtain the toxin profiles of
the eFORS outbreaks. For those outbreaks in which an HUS rate and toxin profile was
available, trends were noted to determine if higher HUS rates corresponded to a particular
toxin type.

National Antimicrobial Resistance Monitoring System (NARMS) Dataset
NARMS data provided a third dataset for this study. When NARMS began
surveillance in 1996, there were 14 participating health departments, known as “original
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sites”. In 2003, NARMS participation achieved national coverage with 54 sites. For this
dataset, a simple random sampling scheme was devised, as follows:
1) From the original 14 NARMS sites, a simple random sample of 2 samples per site per
year, (providing a total of 28 samples per year; encompassing 1996-2005) was sampled.
2) Starting with 2003, the year where NARMS increased to 54 sites, a simple random
sample of 4 samples per site for 10 of the 54 sites (these 10 sites were selected randomly)
per year, (providing an additional 40 samples per year; encompassing 2003-2005) was
sampled.
The purpose of the random sampling to create the NARMS dataset was to confirm
any trends seen in the PulseNet and eFORS datasets, by using a more random selection of
isolates than in the latter two data sources. Additionally, NARMS data may be more
representative of STEC O157 in the population, as PulseNet and eFORS are biased
toward outbreak cases.

Toxin Types of Isolates within NARMS Dataset
The sum total of isolates in the NARMS dataset was 363 isolates. Random
sampling of NARMS isolates was performed in order to confirm any trends seen in the
PulseNet and eFORS datasets. For all NARMS isolates, toxin types were determined by
PCR of the toxin genes for Stx1 and Stx2 using a published primer set (Paton 1998), and
PFGE was performed. Both laboratory tests were performed at the CDC. Toxin profiles
and PFGE patterns were evaluated to determine any trends during the time period 19962005.
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Microbiological Methods: PCR Testing and PFGE Analysis
The PulseNet dataset included only isolates with known toxin information. To
obtain toxin information, PCR analysis was performed and results were submitted to the
PulseNet E. coli National Database by the submitting laboratory. PCR was also
conducted by laboratorians at the CDC on isolates within the NARMS dataset, using the
Paton primer set. This is a two-tiered approach to PCR analysis of fecal samples from
patients with suspected STEC infection. Fecal culture extracts are initially screened for
the presence of Stx genes using a pair of redundant oligonucleotide primers capable of
detecting the amplification of a product from either Stx1 or Stx2 (including all known
Stx2 subtypes associated with human disease). Any extracts yielding a positive result are
subjected to a second round of analysis using two multiplex PCR assays, which provide
confirmation of the presence of Stx genes (Paton A. 2003).
PFGE patterns submitted to the PulseNet national database by PulseNet certified
laboratorians are prepared using a standardized protocol (Ribot 2006). In this procedure
genomic DNA is prepared by embedding cells in agarose plugs and lysing the cells using
lysozyme, sarcosyl, and deoxycholate with subsequent washes in a buffer solution. The
DNA is digested in the agarose using the restriction enzyme XbaI. The plugs are placed
in a 1.2% agarose gel. The restricted fragments are separated by PFGE using 0.5 X Trisborated-EDTA buffer at 14 degree Celsius and Chef Dr III (Bio-Rad; Hercules,
California, U.S.) gel apparatus. Conditions for electrophoresis is as follows: initial switch
time, 2.2 seconds, final switch time, 63.8 seconds at an angle of 120 degrees at 6
Volts/centimeter for 20 hours. Restriction fragments are visualized using an ethidium
bromide stain under ultra-violet light, and the PFGE pattern is photographed, digitized,
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and saved as Tagged Image File Format (TIFF). These TIFFs are then analyzed using a
customized software program called BioNumerics (Applied Maths, Saint-Martens Latem,
Belgium).
By standardizing subtyping protocols and analysis tools, the patterns generated in
the PulseNet network may be compared between laboratories. An essential feature of the
PulseNet system is the use of a universal standard by all participants, which is run in
every fourth to fifth lane in all gels, thus allowing for reliable normalization of the
patterns of the isolates in the adjoining lanes. This standard, comprised of XbaI restriction
fragments of Salmonella Braenderup strain H9812 is used as a reference DNA fragment
size standard for all pathogens under surveillance in PulseNet (Hunter et al., 2005).
All PFGE profiles are assigned pattern names by PulseNet database managers. A
PulseNet standardized pattern name consists of 11 characters in the format:
XXXYYY.####. The first three characters (X) represent the organism (e.g., EXH is the
code for STEC O157); the next three characters (Y) represent the restriction enzyme that
was used to cut the DNA (e.g., X01 is the code that represents the enzyme XbaI); the four
digits to the right of the decimal (#) are consecutive numbers assigned to new profiles as
they are detected. This number ascends from 0001 and in no way indicates any kind of
genetic relatedness between different patterns (Gerner-Smidt 2006).

Correlation of PFGE Patterns with Toxin Types
In the PulseNet dataset, isolates were analyzed to determine if certain PFGE
patterns correlated with specific toxin profiles. The top 10 PFGE patterns (XbaI) in the E.
coli national database were identified, based on their frequency of occurrence in the
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national database between 1999 and 2008 (Table 3). These top 10 patterns were
compared across each of three groups of isolates, (classified by their toxin profile as
Stx1-only, Stx2-only, and Stx1+Stx2), to determine if any of the top 10 patterns
correlated with a specific toxin profile.
Table 3: Top 10 PFGE patterns (XbaI) in the E. coli national database, based on
their frequency of occurrence in the national database between 1999 and 2008.
(Total XbaI patterns = 4,357)
Source: CDC PulseNet E. coli national database, 2008

PFGE-XbaI-pattern

Occurrence

Frequency

EXHX01.0047

517

11.90%

EXHX01.0074

202

4.60%

EXHX01.0200

152

3.50%

EXHX01.0224

150

3.40%

EXHX01.1343

131

3.00%

EXHX01.0124

121

2.80%

EXHX01.0125

114

2.60%

EXHX01.0087

102

2.30%

EXHX01.0008

102

2.30%

EXHX01.1486

84

1.90%

Correlation of Non-O157 STEC Serotypes and Toxin Types
In this study, the PulseNet dataset was comprised of STEC O157 isolates only.
However, as of December 2008, approximately 18% of the PulseNet national database
was comprised of non-O157 STEC isolates, and the number of non-O157 STEC isolates
submitted to the database has increased tremendously in recent years as detection
methods have changed in the clinical laboratories. All human non-O157 STEC isolates
from the USA submitted to the PulseNet national database between 1999 and 2008 with
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known toxin information were grouped into a separate subset of 1,422 isolates. The top
six non-O157 serotypes were identified based on their frequency within this group of
isolates. Toxin profiles were examined for the isolates belonging to the top six serotypes
to determine if certain toxin profiles were more predominantly seen in common nonO157 STEC serotypes than in isolates of STEC O157.

Data Analysis
Data were analyzed in SAS 9.1 (SAS Institute, Inc., Cary, NC, USA). A CochranArmitage test was used to test for an increase in Stx2-only producing strains over time.
Trend analyses were performed for all isolates in the PulseNet dataset, as well as
separately for outbreak and sporadic isolates. Trend analyses were also performed for all
isolates in the NARMS dataset. The null hypothesis was that the proportion of Stx2-only
strains did not increase over time. Because the alternative hypothesis was that the
proportion of Stx2-only isolates increased over time, the one-sided p-value is reported.
The Wilcoxon Rank-sum test was used to assess differences in median age. For
categorical variables (i.e., gender), differences were examined using a Chi-Square test.

CHAPTER IV: RESULTS
I. PulseNet Dataset
Distribution of Toxin Types: PulseNet Dataset
PFGE patterns of 4,402 STEC O157 isolates with known toxin information were
submitted between 1999 and 2008 from public health laboratories and food regulatory
agencies within the United States. Table 4 shows the number of isolates with each toxin
type that was submitted per year. The percentage of isolates expressing Stx1-only was
consistently low, and decreased from 2.3% in 1999 to 0.97% in 2008. The percentage of
isolates expressing Stx1+Stx2 decreased from a high of 86.2% in 1999 to a low of 41.8%
in 2008. The percentage of isolates expressing Stx2-only increased from a low of 11.5%
in 1999 to a high of 57.2% in 2008 (Figure 9). (Cochran-Armitage trend test for increase
in Stx2-only strains: Z=13.4; p<0.0001).

Table 4: Distribution of Toxin Types, 1999-2008: [PulseNet Dataset, (n=4402)]

1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
Total

Isolates with Stx1-only
(%)
2 (2.3%)
0 (0.0%)
3 (2.5%)
19 (7.9%)
1 (0.4%)
5 (1.0%)
9 (1.5%)
11 (1.3%)
10 (1.3%)
9 (0.97%)
69

Isolates with Stx1+Stx2
(%)
75 (86.2%)
38 (82.6%)
89 (73.6%)
168 (69.4%)
155 (62.8%)
267 (54.3%)
338 (54.6%)
375 (44.5%)
382 (49.2%)
389 (49.8%)
2276
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Isolates with
Stx2-only (%)
10 (11.5%)
8 (17.4%)
29 (24.0%)
55 (22.7%)
91 (36.8%)
220 (44.7%)
272 (43.9%)
456 (54.2%)
384 (49.5%)
532 (57.2%)
2057

Total
87
46
121
242
247
492
619
842
776
930
4402
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Figure 9: Distribution of Toxin Types (percentage of isolates), 1999-2008: [PulseNet
Dataset, (n=4402)]
Cochran-Armitage trend test for an increase in Stx2-only strains: Z=13.4; p<0.0001
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Distribution of Toxin Types: Sporadic vs. Outbreak-Related Isolates
The isolates within the PulseNet dataset were separated into outbreak-related
isolates and sporadic isolates using the PulseNet-assigned outbreak code, to assess
whether similar trends in toxin types existed among both outbreak and sporadic isolates.
2,519 isolates were classified as sporadic cases and 1,629 isolates were classified as
outbreak-related cases. The distribution of toxin types was evaluated for both sets of
isolates. Only isolates from 2002-2008 were included, as PulseNet did not utilize
outbreak codes prior to 2002. The trends in toxin types for sporadic isolates are shown in
Table 5 and Figure 10. The trends in toxin types for outbreak-related isolates are shown
in tables 6 and Figure 11. (Cochran-Armitage trend test for increase in sporadic Stx2-only
strains: Z=7.95; p<0.0001). (Cochran-Armitage trend test for increase in outbreak-related
Stx2-only strains: Z=4.5; p<0.0001).
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Table 5: Distribution of Toxin Types, Sporadic Isolates, 2002-2008: [PulseNet
Dataset, (n=2519)]

2002
2003
2004
2005
2006
2007
2008
Total

Isolates with Stx1-only
(%)
15 (7.5%)
1 (0.5%)
5 (1.3%)
9 (3.4%)
9 (2.2%)
9 (1.9%)
9 (1.6%)
57

Isolates with Stx1+Stx2
(%)
143 (71.5%)
130 (63.1%)
224 (59.4%)
135 (50.6%)
190 (45.8%)
258 (53.4%)
243 (42.6%)
1323

Isolates with Stx2only (%)
43 (21.5%)
75 (36.4%)
148 (39.3%)
123 (46.1%)
216 (52.0%)
216 (44.7%)
318 (55.8%)
1139

Total
201
206
377
267
415
483
570
2519

Figure 10: Distribution of Toxin Types, Sporadic Isolates (percentage of isolates),
2002-2008: [PulseNet Dataset, (n=2519)]
Cochran-Armitage trend test for an increase in Stx2-only strains: Z=7.9.5; p<0.0001
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Table 6: Distribution of Toxin Types, Outbreak Isolates, 2002-2008: [PulseNet
Dataset, (n=1629)]
Isolates with Stx1-only
(%)
4 (9.5%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
2 (0.5%)
1 (0.3%)
0 (0.0%)
7

2002
2003
2004
2005
2006
2007
2008
Total

Isolates with Stx1+Stx2
(%)
25 (59.5%)
25 (61.0%)
43 (37.4%)
202 (57.5%)
185 (43.3%)
124 (42.3%)
146 (40.6%)
750

Isolates with
Stx2-only (%)
13 (31.0%)
16 (39.0%)
72 (62.6%)
149 (42.5%)
240 (56.2%)
168 (57.3%)
214 (59.4%)
872

Total
42
41
115
351
427
293
360
1629

Figure 11: Distribution of Toxin Types, Outbreak Isolates (percentage of isolates),
2002-2008: [PulseNet Dataset, (n=1629)]
Cochran-Armitage trend test for an increase in Stx2-only strains: Z=4.5; p<0.0001
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Number of Outbreaks within PulseNet Dataset
Using the PulseNet-assigned outbreak code, the number of outbreaks for each
year was identified for the time period 2002-2008. The number of outbreaks was lowest
in 2003, at 8 outbreaks, and highest in 2005, at 54 outbreaks. The mean number of
outbreaks for all years was 33.1. The mean number of outbreaks for the first half of the
time period (2002-2005) was almost half that of the second half of the time period (20052008), at 25.3 and 46.3 outbreaks, respectively. The number of outbreaks per year, as
seen in the PulseNet database, is shown in Figure 12.

Figure 12: Number of STEC O157 Outbreaks per year, 2002-2008 and Average
Number of Cases in Outbreaks (USA), 2002-2008 [PulseNet Dataset, (n=232
outbreaks)]
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Age Distribution of Toxin Types
Age distributions of each toxin type were also examined using the PulseNet
dataset. There were 3,714 human STEC O157 isolates with toxin and age information in
the dataset. The median age was calculated for each of the toxin types (Stx1-only,
Stx1+Stx2, and Stx2-only), for each year in the time period 1999-2008 (Tables 7-9). In
1999 and 2000, the median age for all isolates with Stx1-only was unknown, as there
were no known ages for any isolates with Stx1-only in these years. The median age for
all isolates with Stx1-only ranged from a low of 1 year in 2003 to a high of 32 years in
2006. The median age for all isolates with Stx1+Stx2 ranged from a low of 13 years in
2007 to a high of 21 years in 2000. The median age for all isolates with Stx2-only ranged
from a low of 5 in 1999 to a high of 40 in 2000. There were no differences in the age
distribution of patients infected with Stx1-only, Stx1+Stx2, or Stx2-only strains, and
there was no change in the age distribution during the time period observed.
Differences in the median age for all years combined (1999-2008) were assessed
for isolates with Stx1+Stx2 and Stx2-only using the Wilcoxon Two-Sample test. The
median age for all isolates with Stx1+Stx2 was 24.3 years, and the median age for all
isolates with Stx2-only was 21.4 years. This difference was found to be statistically
significant (Z=4.9; p<0.0001).
The PulseNet dataset was used to identify if more cases were seen among young
children relative to other ages during 1999-2008. The 3,714 isolates with toxin and age
information were categorized into different age intervals, with five years per interval.
Age intervals ranged from 1-5 years old to 96-100 years old. Results showed that the
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highest number of cases was among the age interval 1-5 years, followed by 6-10 years
and 11-15 years for each toxin type (Figure 13).

Figure 13: Number of STEC O157 Cases Among Age Intervals (USA), 1999-2008
[PulseNet Dataset, (n=3714)]
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Gender Distribution of Toxin Types
3,645 human STEC O157 isolates in the PulseNet dataset contained toxin and
gender information. To identify trends in gender distribution of toxin types using the
PulseNet dataset, all human STEC O157 isolates with known toxin and gender
information were classified into a group of 3,645 isolates. The percentage of female cases
was calculated for each of the three toxin types, for each year in the time period 19992008 (Tables 7-9). In 1999 and 2000, the percentage of female cases for all isolates with
Stx1-only was unknown, as there was no gender information available for any isolates

54
with Stx1-only in these years. There was also no gender information available for isolates
with Stx2-only in 1999. The percentage of female cases for all isolates with Stx1-only
ranged from a low of 50% in 2002 to a high of 66.7% in 2001, 2004, and 2005. The
percentage of female cases for all isolates with Stx1+Stx2 ranged from a low of 46.2% in
2000 to a high of 62.0% in 2001. The percentage of female cases with Stx2-only ranged
from a low of 47.8% in 2004 to a high of 65.4% in 2003. The average percentage of
female cases for all isolates with Stx1-only, Stx1+Stx2, and Stx2-only (for all years in
which gender information was available) was 57.9%, 53.7%, and 54.0%, respectively.
Thus, the average percentage of female cases was above 50% for each of the toxin types
for all years, indicating a slightly higher risk of infection among females. However, this
difference was not found to be statistically significant as determined by a Chi-Square test
(x2=1.37; p=0.2426).

Table 7: Age and Gender Distribution (Age in Years) of Toxin Type Stx1-only,
1999-2008 (USA) [PulseNet Dataset, (age n=51; gender n=54)]
Stx1only

Total Isolates with
Gender Information

Age Distribution
(Years)

1999
2000
2001
2002
2003
2004
2005
2006
2007
2008

N
0
0
3
16
3
6
6
5
8
7

(25%- 75% quartiles)
unknown
unknown
(6 - 28)
(12 - 31)
(1 - 1)
(8.5 - 33)
(2.25 - 12.75)
(15 - 46)
(6.5 - 29.25)
(4.25 - 17.75)

Median
(Age in
years)
unknown
unknown
7
27
1
13
4.5
32
14
15.5

Gender
Distribution
Total Female (%)
Unknown
Unknown
2 (66.7%)
8 (50.0%)
1 (33.3%)
4 (66.7%)
4 (66.7%)
3 (60.0%)
5 (63.0%)
4 (57.0%)
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Table 8: Age and Gender Distribution (Age in Years) of Toxin Type Stx1+Stx2,
1999-2008 (USA) [PulseNet Dataset, (age n=1844; gender n=1847)]

Stx1+Stx2

Total Isolates with
Gender Information

1999
2000
2001
2002
2003
2004
2005
2006
2007
2008

N
15
39
71
146
123
241
278
271
292
371

Age Distribution
(Years)
(25%- 75%
quartiles)
(3 - 56)
(8 - 46)
(7.5 - 45.25)
(6.75 - 42)
(6 - 51.75)
(7 - 44)
(6 - 47)
(4 - 26)
(5.5 - 34.5)
(5 - 32)

Median
(Age in
Years)
19
21
14
18
20.5
14
16
15
13
17

Gender
Distribution
Total Female (%)
8 (53.3%)
18 (46.2%)
44 (62.0%)
71 (48.6%)
74 (60.2%)
132 (54.8%)
153 (55.0%)
142 (52.4%)
150 (51.4%)
196 (52.8%)

Table 9: Age and Gender Distribution (Age in Years) of Toxin Type Stx2-only,
1999-2008 (USA) [PulseNet Dataset, (age n=1819; gender n=1744)]
Stx2only

Total Isolates with
Gender Information

Age Distribution
(Years)

1999
2000
2001
2002
2003
2004
2005
2006
2007
2008

N
0
8
23
46
78
180
208
356
349
496

(25%- 75% quartiles)
(5 - 5)
(4.5 - 58)
(5 - 24.5)
(8 - 54)
(3.5 - 25)
(4 - 25)
(3 - 29.25)
(5 - 27.75)
(4 - 25)
(5 - 31)

Median
(Age in
Years)
5
40
7
20
13
12
9
13
12
13

Gender
Distribution
Total Female (%)
Unknown
4 (50.0%)
13 (56.5%)
29 (63.0%)
51 (65.4%)
86 (47.8%)
104 (50.0%)
187 (52.5%)
185 (53.0%)
240 (48.4%)
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Seasonal Distribution of Toxin Types
Seasonal distributions of toxin types were also evaluated using the PulseNet
dataset. All isolates within the dataset contained an upload date, which served as the
approximate date in which STEC was isolated from the patient. Epidemiologists at the
CDC use PulseNet upload dates to approximate isolation dates in outbreak investigations.
The isolation date is generally estimated to be 14 days earlier than the upload date. Using
the upload date, all isolates were divided into a year-quarter, with quarters making up a
three-month time frame. For example, the first quarter of 2000 comprised all isolates with
an upload date of January 1, 2000 to March 31st, 2000. The seasonal distribution of all
isolates in the dataset ranged from the third quarter of 1999 (no isolates existed in the
database for the 1st or 2nd quarter of 1999) to the 4th quarter of 2008. Each toxin type was
evaluated separately (Figure 14). There was a general seasonal increase between the 2nd
quarter (Q2) and 3rd quarter (Q3) for each toxin type within every year and a general
seasonal decrease between Q3 and the 4th quarter (Q4) for each toxin type within every
year. The number of isolates was consistently lowest during the first quarter (Q1) for
each toxin type and year.
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Figure 14: Seasonal Distributions of Toxin Types by Quarter, 1999-2008 (USA)
[PulseNet Dataset, (n=4312)]
Seasonal Distributions of Toxin Types, by Quarter*
*(Q1=Jan-Mar, Q2=Apr-Jun, Q3-July-Sept, Q4=Oct-Dec)
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Geographic Distribution of Toxin Types
Geographical distributions of toxin types were also evaluated using the PulseNet
dataset. 4,374 isolates within the dataset contained a source state, and source states were
considered to be the state in which the patient became infected with STEC O157:H7. One
map was created for each of the three toxin profiles and showed the geographical
distribution of all isolates with that toxin profile from 1999-2008. Figure 15 shows the
overall geographical distribution of Stx1-only strains for 1999-2008. Figure 15A and 15B
show the geographical distribution of Stx1-only strains in 1999 compared to 2008. Figure
16 shows the overall geographical distribution of Stx1+Stx2 strains for 1999-2008.
Figure 16A and 16B show the geographical distribution of Stx1+Stx2 strains in 1999
compared to 2008. Figure 17 shows the overall geographical distribution of Stx2-only
strains for 1999-2008. Figure 17A and 17B show the geographical distribution of Stx2only strains in 1999 compared to 2008. There were no clear differences between regions,
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except that CA, MI, OH, and VA appeared to have the highest numbers of submissions
for each of the toxin profiles. For isolates with Stx2-only, TX also appeared to have a
higher number of submissions relative to other states.
Figure 15: Overall Geographic Distribution of Isolates with Stx1-only, 1999-2008
(USA) [PulseNet Dataset, (n=67)]

Figure 15A and 16B: Geographic Distribution of Isolates with Stx1-only, 1999 and
2008 (USA) [PulseNet Dataset, (1999 n=2; 2008 n=9)]
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Figure 16: Overall Geographic Distribution of Isolates with Stx1+Stx2, 1999-2008
(USA) [PulseNet Dataset, (n=2265)]

Figure 16A and 16B: Geographic Distribution of Isolates with Stx1+Stx2, 1999 and
2008 (USA) [PulseNet Dataset, (1999 n=74; 2008 n=389)]
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Figure 17: Overall Geographic Distribution of Isolates with Stx2-only, 1999-2008
(USA) [PulseNet Dataset, (n=2042)]

Figure 17A and 17B: Geographic Distribution of Isolates with Stx2-only, 1999 and
2008 (USA) [PulseNet Dataset, (1999 n=10; 2008 n=532)]

Distribution of Toxin Types by PFGE
The PulseNet dataset was also used to identify if certain toxin types were
associated with particular PFGE patterns. The PulseNet-designated PFGE pattern name
was used to make this assessment. The top ten XbaI patterns were identified based on
their frequency of occurrence in the PulseNet dataset between 1999 and 2008. The
percentage of isolates with each toxin type for each of the top ten patterns is shown in
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Figure 18. Figures 19 and 20 show the percentage of isolates with these ten patterns from
1999-2003 and 2004-2008, respectively. For all patterns except EXHX01.1343 and
EXHX01.0008, the percentage of Stx2-only strains increased from 1999-2003 to 20042008. One hundred percent of isolates with pattern EXHX01.1486 had toxin type Stx2only. For patterns EXHX01.0047, EXHX01.0200, EXHX01.0224, EXHX01.0124,
EXHX01.0125, there was a strong association between the toxin profile and PFGE
pattern, as more than 90% of isolates with these patterns were associated Stx2-only. For
patterns EXHX01.0074, EXHX01.1343, EXHX01.0087, and EXHX01.0008, more than
80% of the isolates were associated with Stx1+Stx2. None of the patterns within the top
ten were associated with Stx1-only. Therefore, there seems to be an association between
PFGE pattern and toxin profile for most patterns, although this association is not
absolute.
Additionally, the top five PFGE patterns of isolates with Stx1-only were
identified and were found to be EXHX01.0074, EXHX01.0079, EXHX01.0087,
EXHX01.3417, and EXHX01.3138. When compared against the entire E. coli national
database, the latter two PFGE patterns were only seen with toxin type Stx1-only.
However, each of these patterns had only been seen twice in the entire database, so there
was not a large enough sample to predict that these two patterns are exclusively
associated with Stx1-only producing strains.
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Figure 18: Top 10 E. coli PFGE patterns (XbaI) and their Toxin Types (USA), 19992008, [PulseNet Dataset, (n=1676)]
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Figure 19: Top 10 E. coli PFGE patterns (XbaI) and their Toxin Types (USA), 19992003, [PulseNet Dataset, (n=188)]
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Figure 20: Top 10 E. coli PFGE patterns (XbaI) and their Toxin Types (USA), 20042008, [PulseNet Dataset, (n=1488)
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Distribution of Toxin Types among Non-O157 STEC Isolates
The PulseNet database was also used to evaluate whether certain toxin profiles
were seen at higher frequencies among non-O157 STEC serotypes. The top six non-O157
STEC serotypes were identified based on their frequency in the PulseNet national
database for the time period 1999-2008 (Table 10). The percentage of isolates with each
toxin type was identified for each of the top 6 non-O157 serotypes. For all serotypes,
with the exception E. coli O121, the percentage of isolates with Stx1-only was higher
than the percentage of isolates with Stx1+Stx2 or Stx2-only (Figure 21). The distribution
of toxin types among isolates with E. coli O121 is shown in table 11.
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Table 10: Number of Isolates with Top 6 Non-O157 STEC Serotypes (USA), 19992008 [PulseNet Dataset, (n=1422)]

Serotype
E. coli O26
E. coli O111
E. coli O103
E. coli O121
E. coli O45
E. coli O145

Occurrence
249
207
157
101
91
39

Frequency (n=1422)
17.5%
14.6%
11.0%
7.1%
6.4%
2.7%

Figure 21: Distribution of Toxin Types among Top 6 Non-O157 STEC Serotypes
(USA), 1999-2008 [PulseNet Dataset, (n=1422)]
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Table 11: Distribution of Toxin Types among E. coli O121 isolates (USA), 20032008* [PulseNet Dataset, (n=101)]

2003
2004
2005
2006
2007
2008

Stx1-only
0
1
0
1
0
0

Stx1+Stx2
0
0
0
1
0
1

Stx2-only
6
8
4
14
47**
18

*No E. coli O121 isolates with known toxin information were submitted to the PulseNet
database prior to 2003
**Number of isolates in 2007 with Stx2-only was elevated due to an outbreak in a prison

II. eFORS Dataset
Number of Outbreaks Within eFORS Dataset
The number of STEC outbreaks reported to eFORS was identified for the years
1998-2006 (n=233) and is shown in figure 22. There were no observable trends seen in
the number of outbreaks during this time period. The number of outbreaks ranged from a
low of 17 outbreaks in 2004 to a high of 33 outbreaks in 2006. The average number of
outbreaks for all years was 25.8.

66
Figure 22: Number of STEC O157 Outbreaks Reported to eFORS, 1998-2006
[eFORS Dataset, (n=233 outbreaks)]
STEC O157 Outbreaks Reported to eFORS, 1998-2006 (mean =25.8)
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HUS Rates of Outbreaks and Toxin Types
HUS rates were available for 166 (71.2%) of the 233 outbreaks in the eFORS
dataset and were compared for each year during 1998 to 2006 to determine trends. HUS
rates were calculated by dividing the number of HUS cases in the outbreak by the number
of cases in the outbreak in which an HUS status was known. The number of outbreaks in
the eFORS dataset with known HUS rates ranged from a low of 6 in 1998 to a high of 31
in 2006 (Table 12). The average HUS rate was determined for all outbreaks occurring in
each year (Figure 23). The average HUS rate ranged from a low of 0.40% in 1998 to a
high of 16.1% in 2006.
Toxin information was only available for 43 (25.9%) of the 166 outbreaks with
known HUS rates. No toxin information was available for any outbreaks occurring prior
to 2000. Three outbreaks were caused by Stx1-only producing strains; one in 2000 (HUS
rate = 45.5%), one in 2002 (HUS rate unknown), and one in 2005 (HUS rate = 0.0%).
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Seventeen outbreaks occurring between 2001 and 2006 were caused by Stx1+Stx2producing strains, and HUS rates for these outbreaks ranged from 0.0% to 50.0% (the
outbreak with an HUS rate of 50.0% only contained three cases, of which two had an
HUS status, one positive and one negative). There were 23 outbreaks with toxin type
Stx2-only which were exclusively seen in 2005 and 2006, with the exception of two that
occurred in 2003. The HUS rates for these outbreaks ranged from 0.0% to 50.0% (the
outbreak with an HUS rate of 50.0% only contained 8 cases, of which all had an HUS
status, 4 positive and 4 negative). These results are shown in table 13.

Table 12: Number of STEC O157 Outbreaks Submitted to eFORS with Available
HUS Rates, 1998-2006 [eFORS Dataset, (n=166)]

Year

Number of Outbreaks
Submitted with HUS Rates

1998

6

1999

14

2000

22

2001

14

2002

20

2003

18

2004

16

2005

25

2006

31
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Figure 23: Average HUS Rates of STEC O157:H7 Outbreaks Submitted to eFORS,
1998-2006 [eFORS Dataset, (n=166)]
Average HUS Rates of STEC O157:H7 Outbreaks Submitted to eFORS, 1998-2006
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Table 13: HUS Rates of STEC O157:H7 Outbreaks Submitted to eFORS with
Available Toxin Information, 1998-2006 [eFORS Dataset, (n=43)]
Year of
Outbreak

Month of
Outbreak

Estimated Total
Cases

Cases with Known
HUS Information

HUS Cases

HUS Rate

Toxin

2000

Apr

15

11

5

45.5%

stx1*
stx1+2

2001

Oct

28

28

0

0.0%

2002

Aug

74

unknown

1

unknown

stx1

2002

Aug

16

unknown

unknown

unknown

stx1+2

2003

Aug

18

6

2

33.3%

stx1+2

2003

Apr

13

unknown

3

unknown

stx2

2003

Oct

16

unknown

unknown

unknown

stx2

2004

Apr

59

29

7

24.1%

stx1+2

2004

May

4

4

0

0.0%

stx1+2

2004

Nov

6

6

0

0.0%

stx1+2

2005

Aug

52

52

0

0.0%

stx1

2005

May

3

3

0

0.0%

stx1+2

2005

June

8

8

0

0.0%

stx1+2

2005

Aug

18

18

2

11.1%

stx1+2

2005

Sept

34

30

2

6.7%

stx1+2

2005

Oct

64

64

0

0.0%

stx1+2

2005

Oct

12

12

0

0.0%

stx1+2

2005

Jan

3

unknown

unknown

unknown

stx2

2005

Jan

2

2

0

0.0%

stx2

2005

Apr

60

60

8

13.3%

stx2

2005

Aug

6

6

0

0.0%

stx2
stx2

2005

Aug

5

5

0

0.0%

2005

Sept

14

14

1

7.1%

stx2

2005

Oct

4

4

0

0.0%

stx2

2005

Oct

9

7

0

0.0%

stx2

2005

Oct

3

3

0

0.0%

stx2

2005

Nov

18

15

3

20.0%

stx2

2006

Jan

2

2

0

0.0%

stx1+2

2006

Mar

2

2

0

0.0%

stx1+2

2006

May

3

2

1

50.0%

stx1+2

2006

Aug

5

5

0

0.0%

stx1+2

2006

Sept

6

6

2

33.3%

stx1+2

2006

Mar

6

6

1

16.7%

stx2

2006

Apr

7

7

1

14.3%

stx2

2006

May

4

4

1

25.0%

stx2

2006

June

5

5

1

20.0%

stx2

2006

June

3

3

1

33.3%

stx2

2006

June

2

2

0

0.0%

stx2

2006

Aug

4

4

1

25.0%

stx2

2006

Aug

8

8

4

50.0%

stx2

2006

Nov

3

3

0

0.0%

stx2

2006

Dec

21

21

0

0.0%

stx2

2006

Aug

3

3

1

33.3%

stx2
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* It is possible that the strain causing this outbreak originated with Stx1+Stx2, but subsequently lost the
phage that produces the Stx2 toxin gene.

III. NARMS Dataset
Distribution of Toxin Types within NARMS Dataset
The NARMS dataset was used to identify trends in toxin profiles for the time
period 1996-2005. The number and percentage of isolates with each toxin type was
calculated for each year and are shown in table 14 and figure 24, respectively. The
percentage of isolates with Stx1-only remained very low in all years. The percentage of
isolates with Stx1+Stx2 decreased from a high of 79.2% in 1996 to 50.0% in 2005. The
percentage of isolates with Stx2-only increased from 20.8% in 1996 to a high of 45.0% in
2005. Cochran-Armitage trend test for an increase in Stx2-only strains: Z=2.32;
p<0.0101.
In all years except for 1996, 1997, and 1999, there was a small percentage of
isolates in which the PCR reaction failed due to no amplification (na). These isolates
were repeated with a different PCR assay, which differed from the original assay by
targeting slightly different regions of the Stx genes. Some isolates still revealed no
amplification, which may have been due to mutations in the toxin genes, or the organism
being non-toxigenic O157, which would have led to the toxin genes being absent or too
broken to be amplified.
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Table 14: Number of Isolates with each Toxin Type (na: no amplification), 19962005 [NARMS Dataset, (n=363)]
Isolates with Stx1-only
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
1 (3.6%)
0 (0.0%)
3 (5.0%)
1 (1.7%)
5

1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
Total

Isolates with
Stx1+stx2
19 (79.2%)
13 (56.5%)
19 (73.1%)
19 (70.4%)
14 (50.0%)
15 (53.6%)
14 (50.0%)
29 (50.0%)
29 (48.3%)
30 (50.0%)
201

Isolates with
Stx2-only
5 (20.8%)
10 (53.5%)
5 (19.2%)
8 (29.6%)
12 (43.0%)
12 (42.9%)
10 (35.7%)
21 (36.2%)
21 (34.4%)
27 (45.0%)
131

na

Total

0 (0.0%)
0 (0.0%)
2 (7.7%)
0 (0.0%)
2 (7.1%)
1 (3.6%)
3 (10.7%)
8 (13.8%)
8 (13.3%)
2 (3.3%)
26

24
23
26
27
28
28
28
58
61
60
363

Figure 24: Distribution of Toxin Types (percentage of isolates), 1996-2005 [NARMS
Dataset, (n=363)]
Cochran-Armitage trend test for an increase in Stx2-only strains: Z=2.32; p<0.0101
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Stx2 Toxin Subtypes within NARMS Dataset
Stx2 toxin subtypes (a,c) were evaluated for all isolates in the NARMS dataset
with either toxin type Stx1+Stx2 or Stx2-only. The percentage of isolates with each of the
toxin subtypes Stx1+Stx2a, Stx1+Stx2c, Stx2a, and Stx2c were identified (Table15,
Figure 25). The percentage of isolates with Stx1+Stx2a decreased from 75.0% in 1996 to
45.0% in 2005. There were no significant trends in the percentage of isolates with
Stx1+Stx2c or Stx2a between 1996 and 2005. The percentage of isolates with Stx2c
increased from 4.2% to a high of 26.7% in 2005. Therefore, the decrease in the frequency
of isolates with Stx1+Stx2 is almost exclusively a decrease in Stx1+Stx2a, whereas the
increase in Stx2-only is mainly caused by an increase in Stx2c.

Table 15: Stx2 Toxin Subtypes of STEC O157 Isolates (na: no amplification), 19962005 [NARMS Dataset, (n=363)]

1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
Total

Number of Isolates
in Dataset
24
23
26
27
28
28
28
58
61
60
363

Stx1+Stx2a
18 (75.0%)
13 (56.5%)
19 (73.1%)
18 (66.7%)
12 (42.9%)
14 (50.0%)
14 (50.0%)
27 (46.6%)
26 (42.6%)
27 (45.0%)
188

Stx1+Stx2c
1 (4.2%)
0 (0.0%)
0 (0.0%)
1 (3.7%)
2 (7.1%)
1 (3.6%)
1 (3.6%)
3 (5.2%)
3 (4.9%)
3 (5.0%)
15

Stx2a
4 (16.7%)
8 (34.8%)
2 (7.7%)
6 (22.2%)
11 (39.3%)
7 (25.0%)
4 (14.3%)
13 (22.4%)
7 (11.5%)
11 (18.3%)
73

Stx2c
1 (4.2%)
2 (8.7%)
3 (11.5%)
2 (7.4%)
1 (3.6%)
5 (17.9%)
6 (21.4%)
8 (13.8%)
14 (23.0%)
16 (26.7%)
58

na
0 (0.0%)
0 (0.0%)
2 (7.7%)
0 (0.0%)
2 (7.1%)
1 (3.6%)
3 (10.7%)
7 (12.1%)
11 (18.0%)
3 (5.0%)
29

73

Figure 25: Stx2 Toxin Subtypes of STEC O157 Isolates (percentage of isolates) (na:
no amplification), 1996-2005 [NARMS Dataset, (n=363)]

Stx2 Toxin Sub-types of STEC O157 Isolates (na: no amplification), 1996-2005 [NARMS
Dataset (n=363)]
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CHAPTER V: DISCUSSION
Study Significance
STEC O157:H7 is responsible for causing approximately 73,000 illnesses and 61
deaths annually in the United States (Mead, 1999). All STEC produce one or both of two
Shiga toxins, Stx1 and Stx2. Findings from previous studies indicate that STEC strains
that produce Stx2 are more strongly associated with HUS than strains that produce both
Stx1 and Stx2 or only Stx1. In recent years, CDC epidemiologists seem to have noticed a
recent increase in the rate of HUS among STEC outbreaks. Such an increase could be due
to a shift in the toxin type produced by STEC strains. In an effort to identify if such a
shift exists, this study compares the toxin profiles of human STEC O157 strains within
three independent datasets, collected by PulseNet, eFORS, and NARMS. The trends in
HUS rates reported through eFORS were also studied.

Important Study Findings
It was hypothesized that 1) there has been an increase in the number of foodborne
outbreaks caused by STEC O157:H7 during the time period 1999-2008 and 2) there has
been an increase in the number of STEC O157:H7 strains that produce Shiga toxin 2-only
during the time period of 1999-2008. The study findings discussed below illustrate that
the first hypothesis is probably not true whereas the latter may be true according to the
data analyzed.
Results from the PulseNet dataset show that since 2002, the number of foodborne
outbreaks caused by STEC O157:H7 has increased, whereas the number of outbreaks
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reported through eFORS did not show any trends from 1998-2006, with an annual
average reported number of 25.8 outbreaks. Fewer outbreaks were reported in PulseNet
in 2002-2004 than in eFORS, whereas the number of outbreaks reported in PulseNet was
higher than in eFORS for the years 2005-2006. This indicates that significant underreporting of outbreaks took place in PulseNet until 2004. It is to be expected that the
number of outbreaks detected in PulseNet is higher than in eFORS, since the eFORS
database only contains confirmed outbreaks whereas the PulseNet database also includes
clusters that are not investigated epidemiologically. A reason for the under-reporting in
PulseNet in 2002-2004 may be that during the early years following introduction of
cluster codes, clusters were predominantly assigned cluster codes if they were
investigated by epidemiologists. Since 2004, all clusters detected by PulseNet have been
assigned a cluster code.
In the PulseNet dataset, the number of outbreaks was lowest in 2003 at 8
outbreaks and highest in 2005 at 54 outbreaks. However, after 2005, the number of
outbreaks gradually decreased to a low of 39 outbreaks in 2008. The average number of
outbreaks per year as seen in the PulseNet dataset was 33.1. The increase in the number
of outbreaks per year in the PulseNet dataset may be artificial for the reason explained
above and perhaps because of improved cluster detection and expansion of the PulseNet
network. The number of outbreaks for 1999-2001 was not available, as PulseNet did not
begin using outbreak codes until 2002.
In contrast to the results found using the PulseNet dataset, there was not a gradual
increase in the number of outbreaks reported to eFORS during the time period 1998-2006
(data for 2007 and 2008 were not available). The number of outbreaks reported to eFORS

76
ranged from a low of 17 outbreaks in 2004 to a high of 33 outbreaks in 2006. The
average number of outbreaks per year as seen in the eFORS dataset was 25.8.
Results from this study also show that since 1999, the number of STEC O157:H7
strains that produce Shiga toxin 2-only has increased. The PulseNet dataset of 4,402
isolates showed a gradual increase in the number of strains producing Stx2-only from
1999 to 2008. The percentage of isolates producing Stx2-only increased from a low of
11.5% in 1999 to a high of 57.2% in 2008. This increase was found to be statistically
significant (p< 0.0001). This increase occurred in parallel to a gradual decrease in the
percentage of isolates producing Stx1+Stx2.
When isolates within the PulseNet dataset were separated into outbreak isolates
and sporadic isolates, the same trend was seen. Among the 1,629 outbreak isolates, the
percentage of isolates producing Stx2-only increased from a low of 31.0% in 2002 to a
high of 59.4% in 2008. Among the 2,519 sporadic isolates, the percentage of isolates
producing Stx2-only increased from a low of 21.5% in 2002 to a high of 55.8% in 2008.
These increases were found to be statistically significant (p<0.0001).
Results from the eFORS dataset also showed an increase in the number of
outbreaks producing Stx2-only relative to the other toxin types for the time period 20002006 (Figure 22). No toxin information was available for any of the outbreaks prior to
2000. During 2000-2004, there were six outbreaks in which the toxin information was
known, and none of these outbreaks were caused by Stx2-only producing strains. In 2005,
there were 17 outbreaks with known toxin information, of which 10 (58.8%) were caused
by Stx2-only producing strains. In 2006, there were 16 outbreaks with known toxin
information, of which 11 (69.0%) were caused by Stx2-producing strains.
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Additionally, results from the NARMS dataset of 363 isolates showed a gradual
increase in the number of isolates producing Stx2-only during the time period 1996-2005.
The percentage of isolates producing Stx2-only increased from 20.8% in 1996 to 45.0%
in 2005. This increase occurred in parallel to a gradual decrease in the percentage of
isolates producing Stx1+Stx2. Isolates producing Stx1-only remained at a steady low for
all years. This trend was found to be statistically significant (p<0.0101).
Further analysis of the NARMS dataset revealed trends in the Stx2 toxin subtypes
of the isolates. Results in this dataset showed that the increase in Stx2-only producing
strains is mainly caused by an increase in Stx2c. The percentage of isolates with Stx2c
increased from 4.2% in 1996 to 26.7% in 2005. This increase occurred in parallel to a
gradual decrease in the percentage of isolates producing Stx1+Stx2a, indicating that the
decrease in frequency of isolates with Stx1+Stx2 is almost exclusively a decrease in
Stx1+Stx2a.
It was hypothesized that there would be observable trends in the demographic
characteristics (including age and gender) of isolates belonging to each toxin profile for
the time period 1999 to 2008. However, findings from this study show that in humans,
there is no correlation between age and toxin profile of the infecting STEC O157 strain.
Among the 3,714 isolates with a known patient age in the PulseNet dataset, there were no
differences in the median age when the median ages were compared by year, but when
the median age of all isolates were compared for all years combined, the median age of
all isolates with Stx1+Stx2 was different from the median age of all isolates with Stx2only, and this difference was found to be statistically significant (p<0.0001). The median
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ages of patients were compared instead of the mean ages, since the data in the PulseNet
dataset is not normally distributed.
Findings from previous studies specify young age as a risk factor for STEC O157
infection, (Scheiring 2008), which was also found in this study. When the 3,714 isolates
in the PulseNet dataset with toxin and age information were examined by age interval,
the age intervals with the highest numbers of cases were 1-5 years, 6-10 years, and 11-15
years, for each toxin type. Results from this study show that the prevalence of STEC
O157:H7 is a major public health concern because contaminated products may be
consumed by patients of all ages but that young age is a risk factor.
This study also shows a slightly higher risk of infection among females when
toxin profiles were compared between the two genders. In the 3,639 human STEC O157
isolates with known gender information, the average percentage of female cases for all
isolates with Stx1-only, Stx1+Stx2, and Stx2-only was 57.9%, 53.7%, and 54.0%,
respectively. Thus, the percentage of female cases was slightly above 50% for each of the
toxin types. This finding is consistent with results of previous studies that specify female
gender as a risk factor for STEC O157 infections (Scheiring 2008), however, the
difference was not found to be statistically significant in this study (p=0.243).
As hypothesized, this study showed an observable seasonal trend in STEC O157
infections during the time period 1999-2008. Findings showed a general seasonal
increase between the second quarter (April-June) and third quarter (July-September) for
each toxin type within every year, and a general seasonal decrease between the third
quarter and fourth quarter (October-December) for each toxin type within every year. The
number of isolates was consistently lowest during the first quarter (January-March) for

79
each toxin type and year. These data are consistent with results of previous studies that
indicate a marked summer peak in prevalence of STEC O157:H7 (Crump 2003). This
seasonality is unexplained, but is also observed for other bacterial enteric infections and
may be due to ecological factors or increased exposures (ex: recreational water,
undercooked foods served at barbecues, etc.) during warmer summer months.
Results from this study did not illustrate any trends in the geographical
distribution of toxin types. When all isolates from 1999-2008 were combined for each
toxin profile, results showed the highest concentration of cases in California, Michigan,
Ohio, and Virginia, regardless of toxin profile. When isolates of each toxin profile were
compared in 1999 versus 2008, the same states had the highest concentrations of cases.
Higher population densities, agricultural, ranching, and beef processing activities, and/or
the presence of “supershedders” (cattle with greater E. coli O157:H7 transmission
potential) may be contributing factors to the higher concentration of cases in these states.
In addition, Michigan and Virginia serve as PulseNet Area Laboratories. In this role they
provide surge capacity for surrounding states, which may attribute to a higher number of
cases being submitted by these two states. Thus, the observed geographical distribution
could possible be explained by differences in the public health laboratories’ capacity to
perform Stx-type determination.
In this study, PFGE data showed that certain toxin types were associated with
particular PFGE patterns. This finding was based on the top ten PFGE patterns in the E.
coli national database. One hundred percent of isolates with PFGE pattern EXHX01.1486
produced Stx2-only. For patterns EXHX01.0047, EXHX01.0200, EXHX01.0224,
EXHX01.0124, EXHX01.0125, there was a strong association between the toxin profile
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and PFGE pattern, as more than 90% of isolates with these patterns produced Stx2-only.
For patterns EXHX01.0074, EXHX01.1343, EXHX01.0087, and EXHX01.0008, more
than 80% of the isolates produced Stx1+Stx2. None of the patterns among the top 10
produced Stx1-only. This association between toxin type and PFGE pattern is noteworthy
because it suggests that it may be possible to predict the toxin type associated with an
outbreak based on the PFGE pattern of the isolates belonging to the outbreak.
Among the top five PFGE patterns with Stx1-only, there were only two patterns
(EXHX01.3417 and EXHX01.3138) that were exclusively seen with Stx1-only when
compared against the entire E. coli national database; however each of these two patterns
had only been seen twice in the entire database, therefore there was not a large enough
sample to conclude that these patterns are always associated with Stx1-only producing
strains.
It was hypothesized that non-O157 strains would be associated with toxin type
Stx1-only. This hypothesis was found to be true in general, as analysis of the distribution
of toxin types among the top six non-O157 STEC serotypes showed that the percentage
of isolates with Stx1-only was higher than the percentage of isolates with Stx1+Stx2 or
Stx2-only. However, upon a closer look, serotype-specific differences were noticed. In E.
coli O121 strains, the percentage of isolates with Stx2-only was significantly higher than
the other toxin types. Strains of serotype O111 were almost evenly distributed between
Stx1-only and Stx1+Stx2, and all three toxin profiles were almost evenly distributed in
serotype O145. All serotypes contained strains with each toxin profile. These findings
illustrate that outbreaks caused by E. coli O121 may be more severe than outbreaks
caused by other non-O157 STEC serotypes due to the presence of the Stx2 toxin.
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Additionally, the serotype alone should not be used in predicting the risk of severe illness
caused by an STEC strain. As previous studies have indicated, the combined presence of
the eae and Stx2 genes are essential in predicting the severity of illness, rather than the
serotype.
Results from this study do not indicate any trends in HUS rates among STEC
O157 outbreaks in the United States from the time period 1998-2006. HUS rates were
known for 166 (71.2%) of the 233 outbreaks in the eFORS dataset and the average HUS
rate for all outbreaks ranged from 0.40% in 1998 to 16.1% in 2006. However, many of
the HUS rates in the eFORS dataset were much higher than would be expected (as high
as 50.0%), based on outbreaks investigated by CDC epidemiologists and information in
the literature, therefore these data may be unreliable for identifying trends in HUS rates.
Some reported outbreaks seemed to have been caused by strains containing Stx1-only.
However, in many outbreaks, including one out of three Stx1-only producing outbreaks,
the toxin profile was only determined from one strain. Shiga toxins are encoded on
mobile genetic elements, called phages, that may be lost. The toxin profile of an outbreak
strain should therefore be determined for several outbreak-related isolates.
An explanation for the unusually high HUS rates seen in the eFORS dataset may
be a systematic reporting error or bias toward preferentially reporting severe illness.
Taking into account that the HUS rates reported to eFORS may be unreliable, no
correlations between toxin profiles and HUS rates were made using this dataset.
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Study Limitations
It is important to discuss the limitations involved in this study. One limitation is
that the PulseNet dataset is that E. coli national database mirrors the surveillance
performed in the states, and sampling and reporting of STEC O157 isolates varies from
state to state. Furthermore, the toxin type and demographic information is not submitted
for every isolate uploaded to the PulseNet database, and therefore this study excludes
isolates where this information was not available. This is a limitation because the dataset
does not include every STEC O157 isolate submitted to the E. coli national database
between 1999 and 2008. However, since over 70 U.S. public health laboratories and
federal regulatory agencies regularly submit isolates to the PulseNet database, this study
assumes isolates included in the PulseNet dataset represent the national trend of infection
(Gerner-Smidt 2006). Another limitation of the PulseNet dataset is that PulseNet data is
biased toward outbreak isolates; therefore, the E. coli national database may not contain
an accurate representation of trends among sporadic isolates. However, the trends seen in
the PulseNet dataset were confirmed by the random sampling of the NARMS dataset.
A limitation of the eFORS dataset is that only 71.2% of STEC outbreaks in the
dataset contained HUS rates, and HUS information was not provided for all patients in
every outbreak. Additionally, only a small percentage (25.9%) of these outbreaks could
be linked to outbreaks in the PulseNet dataset with toxin information. Because HUS is a
nationally notifiable disease, eFORS is biased toward HUS cases (CDC-DISSS 2009).
This also showed up in many of the outbreaks in the eFORS dataset, where the HUS rates
were unrealistically high and not representative of typical STEC O157 outbreaks.
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A limitation of the NARMS dataset is that a small percentage of the isolates
included in the dataset revealed no amplification following PCR testing. These isolates
were repeated with a different PCR assay, which differed from the original assay by
targeting slightly different regions of the Stx genes. Some isolates still revealed no
amplification, which may have been due to mutations in the toxin genes, or the organism
being non-toxigenic O157, which would have led to the toxin genes being absent or too
broken to be amplified. However, since the number of non-amplifying isolates was low,
this limitation would have little effect on the conclusions from this part of the study.
Another limitation of the study was that the three datasets all contained isolates
from slightly different time periods; the PulseNet dataset contained isolates from 19992008, the eFORS dataset contained isolates from 1998-2006, and the NARMS dataset
contained isolates from 1996-2005. The time frames for the PulseNet and eFORS dataset
were defined to represent the most comprehensive information that was available in each
dataset, while the time frame for the NARMS dataset was defined by a randomized
sampling scheme of available isolates. The sample sizes of each dataset also differed for
each dataset which may also be a limitation to this study.

Recommendations and Future Studies
It is recommended to compare toxin profiles of STEC O157 strains to HUS rates
from a different data source. The data source used in this study for capturing HUS rates
was biased toward HUS cases, leading to unreliably high HUS rates among STEC O157
outbreaks. Additionally, in this study, outbreaks in one dataset (eFORS) had to be linked
with outbreaks in another dataset (PulseNet) to obtain the toxin profiles of those
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outbreaks. It is recommended that state and public health laboratories submit as much
information as possible to each of these data sources, allowing the data to be linked more
efficiently.
Future studies could investigate trends in toxin profiles among non-human
isolates; i.e. food sources and animal reservoirs. This study revealed an increase in the
number of strains producing Stx2-only relative to strains producing Stx1-only and
Stx1+Stx2, therefore it would be reasonable to assume that the same trend exists in the
food commodities and animal reservoirs that are responsible for causing illness in
humans. The data obtained from such a study could be used to understand if certain food
commodities are associated with certain toxin profiles which may cause more severe
illness in humans. Additionally, future studies could examine if the shift in toxin profiles
seen in this study also exists in other countries. Because of the global nature of today’s
food supply, it is likely that these trends are mirrored in other parts of the world.

CHAPTER VI: CONCLUSIONS

Shiga toxin-producing Escherichia coli (STEC) O157:H7 is a major cause of
foodborne illness in the United States and causes severe gastroenteritis and may cause
life-threatening HUS, the most serious complication of STEC infection. One of the main
virulence factors of STEC infections is the production of one or more type of Shiga toxin
(Stx1, Stx2, or both).
The first aim of this study was to determine if data collected from two
independent datasets showed an increase in the number of outbreaks caused by STEC
O157:H7 during the time period 1999-2008. Using the PulseNet E. coli national database
and outbreaks reported to eFORS, the number of outbreaks occurring within each year
was determined based on PulseNet-assigned outbreak codes. The overall conclusion is
that there were no observable trends in the number of outbreaks occurring since 2002.
The second aim of this study was to determine if data collected from three
independent datasets showed an increase in the number of STEC O157:H7 strains that
produce Shiga toxin 2-only. The PulseNet dataset showed a gradual increase in the
number of strains producing Stx2-only from 1999 to 2008, in parallel to a gradual
decrease in the percentage of isolates producing Stx1+Stx2. The same trend was seen
when outbreak-related isolates were separated from sporadic isolates. The eFORS and
NARMS datasets also showed an increase in the number of outbreaks producing Stx2only relative to the other toxin types for the time period observed. Further analysis of the
NARMS dataset revealed that the increase in Stx2-only producing strains is mainly
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caused by an increase in Stx2c, relative to Stx2a. Thus, a shift in the toxin profiles
has changed during the study period.
The third aim of this study was to determine if data collected from eFORS reports
showed an increase in the HUS rates of STEC O157:H7 outbreaks during the time period
observed. However, no conclusions could be made regarding trends in HUS rates based
on the data available in the eFORS dataset since this surveillance system currently seems
to be unreliable for HUS surveillance.
Finally, this study attempted to identify any other observable trends among toxin
profiles of STEC O157 strains. Demographic characteristics including patient age and
gender were examined, in addition to geographical and seasonal trends. Results showed a
higher number of cases among children (1-15 years old) and a slightly higher incidence
of infection among females, regardless of toxin type. Seasonal trends were identified, as
there was a general increase in cases between the second and third quarters of each year,
for each of the three toxin types and a general decrease in cases between the third and
fourth quarters of each year for each toxin type. Analysis of geographical trends revealed
a higher concentration of cases in California, Michigan, Ohio, and Virginia, relative to
other states, for all three toxin profiles, when the years 1999-2008 were combined.
However, the reliability of this finding may be questioned.
Overall, this analysis shows a dramatic shift over time in the toxin profiles of
human STEC O157 strains in the United States towards strains that produce only Stx2.
This shift was observed in three independent databases of mostly sporadic isolates and in
outbreak isolates. No conclusions could be made regarding trends in HUS rates. A
systematic and reliable reporting method of HUS cases among sporadic and outbreak
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associated STEC infections in the United States is warranted in order to understand if a
correlation exists between the severity of this disease and the virulence of the infecting
strain. Further work is needed to determine if a similar trend in toxin profiles of STEC
O157 strains has occurred in animal reservoirs, foods, and other countries. There is a
great need to recognize the trends in toxin profiles of STEC O157 strains in order to fully
understand their potential for causing human illness.
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